

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 49/02, 43/00, G01N 33/53		A1	(11) International Publication Number: WO 94/13327 (43) International Publication Date: 23 June 1994 (23.06.94)
(21) International Application Number: PCT/US93/11842 (22) International Filing Date: 6 December 1993 (06.12.93)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 990,423 15 December 1992 (15.12.92) US		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): STERLING WINTHROP, INC. [US/US]; 9 Great Valley Parkway, Malvern, PA 19355 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SNOW, Robert, A. [CA/US]; 118 Cratin Lane, West Chester, PA 19380 (US). KRUSE, Lawrence, I. [US/US]; 646 Clinton Avenue, Haddonfield, NJ 08033 (US). BLACK, Christopher, D., V. [GB/US]; 2815 Aquarius Avenue, Silver Spring, MD 20906 (US). SHEARMAN, Clyde, W. [US/US]; 607 Chesterville Way, West Chester, PA 19382 (US).			
(74) Agents: KATZ, Martin, L.; Dressler, Goldsmith, Shore & Milnamow, Ltd., Two Prudential Plaza, Suite 4700, Chicago, IL 60601 (US) et al.			

(54) Title: **IMMUNOREACTIVE REAGENTS EMPLOYING DIHYDROFOLATE REDUCTASE**

(57) Abstract

This invention describes a non-radioactive targeting immunoreagent comprised of the residue of a proteinaceous active site of a dihydrofolate reductase enzyme (DHFR), a linking group, and the residue of an immunoreactive material together with a radioactive delivery agent comprised of the residue of a ligand which has an affinity for non-covalent binding to said DHFR receptor moiety, a linking group, and the residue of a radioactive agent. This invention also describes a non-radioactive targeting immunoreagent comprised of the residue of a ligand which has an affinity for non-covalent binding to a DHFR proteinaceous active site receptor moiety, a linking group, and the residue of an immunoreactive material together with a radioactive delivery agent comprised of the residue of a DHFR proteinaceous active site receptor moiety, a linking group, and a radioactive agent. These compositions comprise useful systems for the production of an amplification of delivery of the radioactive agent to tumor sites in the therapy and diagnostic imaging of cancer.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:	A61K 49/02, 43/00, G01N 33/53			(11) International Publication Number:	WO 94/13327	
(21) International Application Number:	PCT/US93/1842			(43) International Publication Date:	23 June 1994 (23.06.94)	
(22) International Filing Date:	6 December 1993 (06.12.93)			(81) Designated States: AU, CA, EP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).		
(30) Priority Date:	15 December 1992 (15.12.92) US			(Published)	With international search report.	
(71) Applicant (for all designated States except US): STERLING WINTHROP, INC. (US/US); 9 Great Valley Parkway, Malvern, PA 19355 (US).						
(72) Inventors; and						
(73) Inventors/Applicants (for US only): SNOW, Robert A. (CA/US); 118 Crain Lane, West Chester, PA 19380 (US); KRUSE, Lawrence L. (US/US); 666 Clinton Avenue, Haddonfield, NJ 08133 (US); BLACK, Christopher D. V. (GB/US); 2615 Aquatics Avenue, Silver Spring, MD 20906 (US); SHEARMAN, Clyde W. (US/US); 607 Clustersville Way, West Chester, PA 19382 (US).						
(74) Agents: KATZ, Martin L.; Dresler, Goldsmith, Shore & Milmanow, Ltd., Two Prudential Plaza, Suite 4700, Chicago, IL 60601 (US) et al.						

(54) Title: IMMUNOREACTIVE REAGENTS EMPLOYING DHYDROFOLATE REDUCTASE

(57) Abstract

This invention describes a non-radioactive targeting immunoreagent comprised of the residue of a proinvasive active site of a dihydrofolate reductase enzyme (DHFR), a linking group, and the residue of an immunoreactive material together with a radioactive delivery agent comprised of the residue of a ligand which has an affinity for non-covalent binding to said DHFR receptor moiety, linking group, and the residue of a radioactive targeting immunoreagent comprised of the residue of a non-radioactive targeting immunoreagent comprised of the residue of a ligand which has an affinity for non-covalent binding to a DHFR proinvasive active site receptor moiety, a linking group, and the residue of an immunoreactive material together with a radioactive delivery agent comprised of the residue of a DHFR proinvasive active site receptor moiety, a linking group, and a radioactive agent. These compositions comprise useful systems for the production of an amplification of delivery of the radioactive agent to tumor sites in the therapy and diagnostic imaging of cancer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	United Kingdom	GB	United Kingdom	MO	Montenegro
AU	Australia	GE	Georgia	MW	Malawi
BR	Brazil	GN	Guinea	NG	Niger
DE	Germany	GR	Greece	NL	Netherlands
ES	Spain	HU	Hungary	NO	Norway
FR	France	IE	Ireland	NZ	New Zealand
IN	India	IT	Italy	PL	Poland
JP	Japan	JP	Japan	PT	Portugal
KR	Korea	KR	Korea	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CL	Chile	KP	Democratic People's Republic of Korea	SD	Sudan
CO	Colombia	KR	Korea	SE	Sweden
CR	Costa Rica	KZ	Republic of Korea	SI	Slovenia
DK	Dominican Republic	KZ	Kazakhstan	SK	Slovakia
ES	Ecuador	LA	Liechtenstein	SL	Singapore
GT	Guatemala	LA	Latvia	TD	Togo
HN	Honduras	LU	Luxembourg	TC	Turkmenistan
IN	India	LV	Lithuania	TT	Trinidad and Tobago
MC	Monaco	MC	Montenegro	UA	Ukraine
MD	Moldova	MD	Republic of Moldova	US	United States of America
MG	Madagascar	MG	Madagascar	UZ	Uzbekistan
ML	Mali	ML	Mali	VN	Viet Nam
MR	Morocco	MR	Morocco	GA	Georgia

IMMUNOREACTIVE REAGENTS EMPLOYING
DIHYDROFOLATE REDUCTASE

Field of the Invention

This invention relates to the therapeutic treatment and diagnostic imaging of cancer by means of a tumor targeted sequential delivery system comprised of a primary non-radioactive targeting immunoreagent and a secondary radioactive delivery agent.

Background of the Invention

The various, currently available, radiolabeled immunoreactive proteins which are employed in diagnostic imaging and targeted therapeutic applications suffer from certain of the following disadvantages:

- 1) toxicity;
- 2) destruction or excretion of the reagent due to rapid catabolism or metabolism;
- 3) inadequate energy of radioactive emission which results in a low signal to noise ratio;
- 4) inefficient covalent bonding of the radioactive component with protein in conjugate preparation;
- 5) long plasma half-lives of currently available radionuclide-containing immunoreactive proteins result in prolonged exposure of normal tissue to damaging effects of radiation that can produce unacceptable toxic effects in otherwise normal and disease free tissues in the body, especially in those tissues and cells most sensitive to radiation damage, e.g., the stem cells of the bone marrow and gastrointestinal tract;
- 6) slow clearance of radionuclide from the body;
- 7) increasing the number of sites of incorporation of radionuclide or chelated radionuclide results in a

5

10

reduction in the capacity of the radionuclide-containing immunoreactive protein to bind to its target;

8) the number of chelating agents that can be attached to an immunoreactive protein is limited by the need to restrict chemical conjugations to sites removed from the immunoreactive recognition or binding sites of the protein;

9) the number of chelating agents that can be attached to an immunoreactive protein is limited by the number of available groups such as, for example, amino groups suitable for use in attachment of the chelating agents;

15) the number of chelating agents that can be attached to an immunoreactive protein is limited by the potential immunogenicity of the thus modified protein which, being highly derivatized, could be recognized by the immune system as haptenated;

16) the number of ionic radionuclides that can be associated with an immunoreactive protein is restricted by the number of sites of chelation available; and

20) 17) radioimmunotherapy and diagnostic imaging with the various currently available radionuclides containing immunoreactive proteins can be less than optimal because these radiopharmaceuticals may bind to non-target normal tissue, which binding can result in undesirable toxicity to normal tissue during therapeutic applications as well as in high background signals during diagnostic imaging applications.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

15

20

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

25

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

30

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

It is an object of the present invention to overcome the aforementioned disadvantages of the currently available radiolabeled immunoreactive proteins.

Symmetry of the Invention

The present invention is directed to systems which are useful in the therapeutic treatment and diagnostic imaging of tissue, particularly of cancerous tissue. For a disease such as cancer, such systems comprise a tumor targeted sequential delivery system comprised of a primary non-radioactive targeting immunoreagent and a secondary radioactive delivery agent.

In one embodiment, the present invention is directed to a non-radioactive targeting immunoreagent (sometimes hereinafter referred to as NRTIR) comprised of the residue of a receptor moiety, a linking group, and the residue of an immunoreactive material, which NRTIR is administered to a tissue of interest and will bind to sites on the surfaces of cells thereof.

In this embodiment, the present invention is also directed to a radioactive delivery agent (sometimes hereinafter referred to as RDA) comprised of the residue of a ligand which has an affinity for non-covalent binding to a receptor moiety, a linking group, and the residue of a radioactive agent. This RDA is administered to the environs of the tissue which contains said NRTIR bound thereto. In particular, the ligand residue of this RDA will non-covalently bind to the receptor of said NRTIR which is bound to the cells of said tissue of interest. Thus, an effective amount of radioactivity is provided to said tissue. RDA which is unbound to NRTIR can be removed rapidly from the environs of the tissue.

In one aspect of this embodiment (sometimes hereinafter referred to as System A), the present invention comprises an NFTIR comprised of the receptor moiety which is comprised of the residues of a dihydrofolate reductase active site of a proteinaceous

enzyme (sometimes hereinafter referred to as a DHFR), a linking group, and the residue of an immunoactive material. In system A, the present invention also comprises an RDA comprised of a ligand which has an affinity for non-covalent binding to a DHFR receptor moiety, a linking group, and the residue of a radioactive agent.

Specifically, in System A, the present invention is directed to an NRTIR comprised of a residue of the proteinaceous active site of a dihydrofolate reductase enzyme, a linking group, and the residue of an immunoreactive material such as a tumor targeting antibody together with an RDA comprised of the residue of a ligand which has an affinity for non-covalent binding to said DHFR receptor moiety, a linking group, and the residue of a radioactive agent comprised of the residue of a chelating agent and a radionuclide.

The NRTIR of system A is comprised of (n) DHFR moieties, each of which can non-covalently bind an RDA comprised of the residue of a ligand with an affinity for non-covalent binding to a DHFR and of (m) radioactive agents where each of n and m is independently an integer greater than zero. The total number of radioactive agents capable of being bound per antigen is then the product of (n) multiplied by (m). This is in contrast to the binding to cell surface antigen of previously available radioimmunoconjugates comprised of an immunoreactive protein conjugated to (c) radioactive agents wherein the value of (c) is an integer greater than zero and is limited to the number of conjugations that can be performed on said immunoreactive protein while retaining the immunoreactivity for said antigen. This limit to the degree of modification of the immunoreactive protein also applies to the NRTIR of System A, and the value of (n) will be approximately the same as the value of (c).

5 Thus, in this aspect, the non-covalent binding of the RDA to the antigen-bound NRTIR of the present invention will amplify the maximum number of radioactive agents bound per antigen by a factor of approximately (m) over the maximum value (c) available in previously available radioimmunoconjugates.

10 In another embodiment, the present invention is directed to an NRTIR comprised of the residue of a ligand which exhibits an affinity for non-covalent binding to a receptor moiety, a linking group, and the residue of an immunoreactive material, which NRTIR is administered to a tissue of interest and will bind to sites on the surfaces of cells thereof.

15 In this embodiment, the present invention is also directed to an RDA comprised of the residue of a receptor moiety for which a ligand has an affinity for non-covalent binding, a linking group, and the residue of a radioactive agent, which RDA is administered to the environments of the tissue which contains the NRTIR of this embodiment bound thereto. In particular, the ligand of the RDA of this embodiment will non-covalently bind to the receptor of the NRTIR which is bound to the surface of the cells of said tissue of interest. Thus, an effective amount of radioactivity is provided to said tissue. RDA which is unbound to NRTIR can be removed rapidly from the environs of the tissue.

20 In particular, in one aspect of this other embodiment (sometimes hereinafter referred to as System B), the present invention comprises a NRTIR comprised of the residue of a ligand which has an affinity for non-covalent binding to a DIFR receptor moiety, a linking group, and the residue of an immunoreactive material.

25 In system B the present invention also comprises an RDA comprised of the residue of a DIFR receptor moiety, a linking group, and the residue of a radioactive agent.

5 Specifically, in System B, the present invention is directed to a NRTIR comprised of the residue of a ligand which has an affinity for non-covalent binding to a DIFR receptor moiety, a linking group, and the residue of an immunoreactive material such as a tumor targeting antibody. In system B the present invention also comprises an RDA comprised of the residue of a DIFR receptor moiety, a linking group, and the residue of a radioactive agent comprised of the residue of a chelating agent and a radionuclide.

10 The NRTIR of System B is comprised of (n) residues of ligands that have an affinity for non-covalent binding to a DIFR, each of which can non-covalently bind an RDA comprised of a DIFR and of (m) radioactive agents where each of n and m is independently an integer greater than zero. The total number of radioactive agents capable of being bound per antigen is then the product of (n) multiplied by (m). This is in contrast to the binding to cell surface antigen of previously available radioimmunoconjugates comprised of an radioactive protein conjugated to (c) radioactive agents. In these conjugates the value of (c) is limited to the number of radioactive agents that can be linked or conjugated to the immunoreactive protein while retaining the immunoreactivity for said antigen. This limit to the degree of modification of the immunoreactive protein also applies to the NRTIR of System B, and the value of (n) will be approximately the same as the value of (c). Thus, in this aspect, the NRTIR of the present invention will amplify the maximum number of radioactive agents bound per antigen by a factor of approximately (m) over the maximum value (c) available in previously available radioimmunoconjugates.

15 The present invention is also directed to pharmaceutical and diagnostic compositions comprising an

7

NRTIR and a pharmaceutically acceptable carrier, and to pharmaceutical and diagnostic compositions comprising an RDA and a pharmaceutically acceptable carrier.

The present invention is further directed to

therapeutic methods comprising the administration, in vitro or in vivo, of a therapeutically effective amount of NRTIR to the environs of a tissue of interest of a patient undergoing such therapy, followed after the lapse of an effective period of time by the subsequent administration of a therapeutically effective amount of RDA to said tissue. During the time between

administrations of NRTIR and RDA said NRTIR binds to sites on cells of the target tissue and unbound NRTIR is removed from the environs of said tissue.

The present invention is further directed to diagnostic imaging methods comprising the sequential administration, in vitro or in vivo, of a diagnostic imaging effective amount of an NRTIR to the environs of a tissue of interest of a patient undergoing such diagnostic imaging, followed after a lapse of an effective period of time by the subsequent administration of a diagnostic imaging effective amount of RDA to said tissue. During said effective period of time said NRTIR will bind to sites on cells of said tissue of interest and unbound NRTIR will be removed from the environs of the tissue. Subsequently, after an effective time, an image of all or part of said tissue of interest is obtained.

The present invention provides advantages compared to currently available targeting immune reagents. For example:

the total amount of a therapeutically effective amount and of a diagnostic imaging effective amount of radioactive agent delivered to a tissue site can be achieved with specificity and in amplification over that

which can be otherwise achieved with currently available targeting immune reagents;

sequential delivery to target tissue of the NRTIR, and the RDA of this invention can reduce the exposure of non-targeted tissues to damage from radiation;

the non-covalent binding of the ligand to the receptor occurs with high affinity and is selective;

the NRTIR and the RDA can be used in both therapeutic and diagnostic imaging applications;

the above-described NRTIR can accumulate at a tumor tissue site in vivo while it is not substantially accumulated at normal tissue sites;

the in vivo residence half life of the above-described NRTIR is long enough to permit its accumulation at a tumor site;

the in vivo residence half life of the above-described RDA is shorter than the residence half life of the above-described NRTIR;

RDA that does not bind to cell associated NRTIR is rapidly cleared from the patient;

with respect to the same degree of modification of a targeting immunoreagent directly conjugated by a radionuclide or by a chelate containing a radionuclide in currently available radioimmunoconjugates, an amplification of the number of radionuclides per site of modification per targeting immune reagent can be obtained using the materials and methods of this invention;

the NRTIR can comprise a wide variety of immunoreactive groups, linking groups, and DFR active site residues in System A, and a wide variety of immunoreactive groups, linking groups, and ligand residues which have an affinity for non-covalent binding to DFR active site residues in System B;

the RDA can comprise a wide variety of spacing, linking and chelating groups, radionuclides, and ligand

9

residues which ligands have an affinity for non-covalent binding to DHFR in System A, and a wide variety of spacing, linking and chelating groups, radionuclides, and DHFR active site residues in System B; and a wide variety of compositions of matter with a wide variety of sizes and molecular weights and having a specificity for accumulation in tumors can be prepared in accordance with this invention.

Other advantageous features of this invention will become readily apparent upon reference to the following description of the preferred embodiments.

Description of Preferred Embodiments

In preferred embodiments, the above-described non-radioactive targeting immunoreagent (NRTIR) and radioactive delivery agent (RDA) are comprised of radioisotopes represented in System A (4 systems) and System B (4 systems) below:

SYSTEM A

	Non-Radioactive Targeting Immunoreagent	Radioactive Delivery Agent	RDA
1	Immunoreactive group + (linking group + receptor) _n	Ligand + (chelating agent + radionuclide) _m	
2	Z-(L ₁ -Rec) _n	D-(L ₂ -Q-M) _m	
3	Z-(L ₁ -Rec) _n	Trimethoprim-(L ₂ -Q-M) _m	
4	Z-(L ₁ -Rec) _n	Methodtrexate-(L ₂ -Q-M) _m	

SYSTEM B

10

wherein:

Z is the residue of an immunoreactive group;
Rec is the residue of a receptor, preferably a DHFR;
D is the residue of a ligand that has an affinity for non-covalent binding to a receptor, preferably to a DHFR receptor;

DHFR ligand is the residue of a ligand that has an affinity for non-covalent binding to a DHFR active site;
TMP is the residue of a ligand comprised of a trimethoprim analog;
MTX is the residue of a ligand comprised of a methotrexate analog;

L₁ and L₂ are each independently the residue of a linking group that may independently contain a spacing group;

Q is the residue of a chelating group;

M is a radionuclide; and

n and m are each independently an integer greater than zero.

20

11

Preferred embodiments of these materials are further described below.

The term "residue" is used herein in context with a chemical entity. Said chemical entity is comprised of, for example, a ligand, or a trimethoprim analog, or a methotrexate analog, or a receptor moiety, or a proteinaceous active site of a dihydrofolate reductase enzyme, or a DHFR, or a chelating group, or a radioactive agent, or a linking group, or a protein reactive group, or an immunoreactive group, or an immunoreactive material, or an immunoreactive protein, or an antibody, or an antibody fragment, or a cross-linking agent such as a heterobifunctional cross-linking agent, or a spacing group. The term "residue" is defined as that portion of said chemical entity which exclusively remains when one or more chemical bonds of which said chemical entity is otherwise comprised when considered as an independent chemical entity, is altered, modified, or replaced to comprise one or more covalent bonds to one or more other chemical entities.

Thus, for example, in one aspect in System A and in System B, the residue of a chelating group is comprised of a chelating group which is at least monovalently modified through attachment to the residue of another chemical entity such as, for example, to the residue of a linking group.

In both System A and System B the immunoreactive group, Z, can be selected from a wide variety of naturally occurring or synthetically prepared materials, including, but not limited to enzymes, amino acids, peptides, polypeptides, proteins, lipoproteins, glyccoproteins, lipids, phospholipids, hormones, growth factors, steroids, vitamins, polysaccharides, viruses, protozoa, fungi, parasites, rickettsia, molds, and components thereof, blood components, tissue and organ components, pharmaceuticals, haptens, lectins, toxins,

nucleic acids (including oligonucleotides), antibodies (monoclonal and polyclonal), anti-antibodies, antibody fragments, antigenic materials (including proteins and carbohydrates), avidin and derivatives thereof, biotin and derivatives thereof, and others known to one skilled in the art. In addition, an immunoreactive group can be any substance which when presented to an immunocompetent host will result in the production of a specific antibody capable of binding with that substance, or the antibody so produced, which participates in an antigen-antibody reaction.

Preferred immunoreactive groups are antibodies and various immunoreactive fragments thereof, as long as they contain at least one reactive site for reaction with the reactive groups on the residue of the receptor moiety in System A or ligand species in System B or with linking groups (L) as described herein. That site can be inherent to the immunoreactive species or it can be introduced through appropriate chemical modification of the immunoreactive species. In addition to antibodies produced by the techniques outlined above, other antibodies and proteins produced by the techniques of molecular biology are specifically included.

As used herein, the term "antibody fragment" refers to an immunoreactive material which comprises a residue of an antibody, which antibody characteristically exhibits an affinity for binding to an antigen. The term affinity, as used herein, refers to the thermodynamic expression of the strength of interaction or binding between an antibody combining site (or other ligand) and an antigenic determinant (or receptor) and, thus, of the stereochemical compatibility between them; as such it is the expression of the equilibrium or association constant for the antibody-antigen (or ligand-receptor) interaction. Antibody fragments exhibit at least a percentage of said affinity for binding to said antigen,

5 nucleic acids (including oligonucleotides), antibodies (monoclonal and polyclonal), anti-antibodies, antibody fragments, antigenic materials (including proteins and carbohydrates), avidin and derivatives thereof, biotin and derivatives thereof, and others known to one skilled in the art. In addition, an immunoreactive group can be any substance which when presented to an immunocompetent host will result in the production of a specific antibody capable of binding with that substance, or the antibody so produced, which participates in an antigen-antibody reaction.

Preferred immunoreactive groups are antibodies and various immunoreactive fragments thereof, as long as they contain at least one reactive site for reaction with the reactive groups on the residue of the receptor moiety in System A or ligand species in System B or with linking groups (L) as described herein. That site can be inherent to the immunoreactive species or it can be introduced through appropriate chemical modification of the immunoreactive species. In addition to antibodies produced by the techniques outlined above, other antibodies and proteins produced by the techniques of molecular biology are specifically included.

As used herein, the term "antibody fragment" refers to an immunoreactive material which comprises a residue of an antibody, which antibody characteristically exhibits an affinity for binding to an antigen. The term affinity, as used herein, refers to the thermodynamic expression of the strength of interaction or binding between an antibody combining site (or other ligand) and an antigenic determinant (or receptor) and, thus, of the stereochemical compatibility between them; as such it is the expression of the equilibrium or association constant for the antibody-antigen (or ligand-receptor) interaction. Antibody fragments exhibit at least a percentage of said affinity for binding to said antigen,

5

10

15

20

25

30

35

12

12

13

said percentage being in the range of 0.001 per cent to 1,000 per cent, preferably 0.01 per cent to 1,000 per cent, more preferably 0.1 per cent to 1,000 per cent, and most preferably 1.0 per cent to 1,000 per cent, of the relative affinity of said antibody for binding to said antigen.

An antibody fragment can be produced from an antibody by a chemical reaction comprising one or more chemical bond cleaving reactions: by a chemical reaction comprising one or more chemical bond forming reactions employing as reactants one or more chemical components selected from a group comprised of amino acids, peptides, carbohydrates, linking groups as defined herein, spacing groups as defined herein, and antibody protein reactive groups as defined herein, and antibody fragments such as are produced as described herein; and by a molecular biological process, a bacterial process, or by a process comprised of a genetic engineering of antibody genes.

An antibody fragment can be derived from an antibody by a chemical reaction comprised of one or more of the following reactions:

(a) cleavage of one or more chemical bonds of which an antibody is comprised, said bonds being selected from, for example, carbon-nitrogen bonds, sulfur-sulfur bonds, carbon-carbon bonds, carbon-sulfur bonds, and carbon-oxygen bonds, and wherein the method of said cleavage is selected from:

(i) a catalysed chemical reaction comprising the action of a biochemical catalyst such as an enzyme such as papain or pepsin which to those skilled in the art is known to produce antibody fragments commonly referred to as Fab and Fab'2, respectively;

(ii) a catalysed chemical reaction comprising the action of an electrophilic chemical catalyst such as a

hydroxium ion which, for example, favorably occurs at a pH equal to or greater than 7;

(iii) a catalysed chemical reaction comprising the action of a nucleophilic catalyst such as a hydroxide ion which, for example, favorably occurs at a pH equal to or greater than 7; and

(iv) a chemical reaction comprised of a substitution reaction employing a reagent which is consumed in a stoichiometric manner such as a substitution reaction at a sulfur atom of a disulfide bond by a reagent comprised of a sulphydryl group;

(v) a chemical reaction comprised of a reduction reaction such as the reduction of a disulfide bond; and

(vi) a chemical reaction comprised of an oxidation reaction such as the oxidation of a carbon-oxygen bond of a hydroxyl group or the oxidation of a carbon-carbon bond of a vicinal diol group such as occurs in a carbohydrate moiety; or

(b) formation of one or more chemical bonds between one or more reactants, such as formation of one or more covalent bonds selected from, for example, carbon-nitrogen bonds (such as, for example, amide bonds, amine bonds, hydrazone bonds, and thiourea bonds), sulfur-sulfur bonds such as disulfide bonds, carbon-carbon bonds, carbon-sulfur bonds, and carbon-oxygen bonds, and employing as reactants in said chemical bond formation one or more reagents comprised of amino acids, peptides, carbohydrates, linking groups as defined herein, spacing groups as defined herein, protein reactive groups as defined herein, and antibody fragments such as are produced as described in (a), above; or

(c) an antibody fragment can be derived by formation of one or more non-covalent bonds between one or more reactants. Such non-covalent bonds are comprised of hydrophobic interactions such as occur in an aqueous medium between chemical species that are

5 hydronium ion which, for example, favorably occurs at a pH equal to or greater than 7;

10 (iii) a catalysed chemical reaction comprising the action of a nucleophilic catalyst such as a hydroxide ion which, for example, favorably occurs at a pH equal to or greater than 7; and

15 (iv) a chemical reaction comprised of a substitution reaction employing a reagent which is consumed in a stoichiometric manner such as a substitution reaction at a sulfur atom of a disulfide bond by a reagent comprised of a sulphydryl group;

20 (v) a chemical reaction comprised of a reduction reaction such as the reduction of a disulfide bond; and

25 (vi) a chemical reaction comprised of an oxidation reaction such as the oxidation of a carbon-oxygen bond of a hydroxyl group or the oxidation of a carbon-carbon bond of a vicinal diol group such as occurs in a carbohydrate moiety; or

30 (b) formation of one or more chemical bonds between one or more reactants, such as formation of one or more covalent bonds selected from, for example, carbon-nitrogen bonds (such as, for example, amide bonds, amine bonds, hydrazone bonds, and thiourea bonds), sulfur-sulfur bonds such as disulfide bonds, carbon-carbon bonds, carbon-sulfur bonds, and carbon-oxygen bonds, and employing as reactants in said chemical bond formation one or more reagents comprised of amino acids, peptides, carbohydrates, linking groups as defined herein, spacing groups as defined herein, protein reactive groups as

35 defined herein, and antibody fragments such as are produced as described in (a), above; or

(c) an antibody fragment can be derived by formation of one or more non-covalent bonds between one or more reactants. Such non-covalent bonds are comprised of hydrophobic interactions such as occur in an aqueous medium between chemical species that are

14

15

15

independently comprised of mutually accessible regions of low polarity such as regions comprised of aliphatic and carbocyclic groups, and of hydrogen bond interactions such as occur in the binding of an oligonucleotide with a complementary oligonucleotide; or

(d) an antibody fragment can be produced as a result of the methods of molecular biology or by genetic engineering of antibody genes, for example, in the genetic engineering of a single chain immunoreactive group or a Fv fragment.

An antibody fragment can be produced as a result a combination of one or more of the above methods.

In certain embodiments, the immunoreactive group can be an enzyme which has a reactive group for attachment to the receptor moiety in System A or ligand species in System B or to a linking group as described below. Representative enzymes include, but are not limited to, aspartane, aminotransaminase, alanine aminotransaminase, lactate dehydrogenase, creatine phosphokinase, gamma glutamyl transferase, alkaline acid phosphatase, prostatic acid phosphatase, horseradish peroxidase and various esterases.

If desired, the immunoreactive group can be modified or chemically altered to provide reactive groups for attaching to the residues of the receptor moiety in System A or ligand species in System B or to a linking group as described below by techniques known to those skilled in the art. Such techniques include the use of linking moieties and chemical modification such as described in WO-A-89/02931 and WO-A-89/9332, which are directed to modification of oligonucleotides, and U.S. Patent No. 4,719,182.

Two highly preferred uses for the compositions of this invention are for the diagnostic imaging of tumors and the radiological treatment of tumors. Preferred immunological groups therefore include antibodies

16


(sometimes hereinafter referred to as "Ab") to tumor-associated antigens. Specific non-limiting examples include B72.3 and related antibodies (described in U.S. Patent Nos. 4,522,918 and 4,612,282) which recognize colorectal tumors, 9.2.27 and related anti-melanoma antibodies, D612 and related antibodies which recognize colorectal tumors, U113A and related antibodies which recognize small cell lung carcinomas, NR11-10 and related antibodies which recognize small cell lung carcinomas and colorectal tumors (Pan-carcinoma), 7E11C5 and related antibodies which recognize prostate tumors, CC19 and related antibodies which recognize colorectal tumors, TNT and related antibodies which recognize necrotic tissue, PR113 and related antibodies which recognize colon carcinoma, ING-1 and related antibodies which are described in International Patent Publication WO-A-90/02559, B174 and related antibodies which recognize squamous cell carcinomas, B43 and related antibodies which are reactive with certain lymphomas and leukemias, and anti-HB and related monoclonal antibodies. An especially preferred antibody is ING-1.

25

Two highly preferred uses for the compositions of this invention are for the diagnostic imaging of tumors and the radiological treatment of tumors. Preferred immunological groups therefore include antibodies

35

17

Scheme 1

5 As used herein, the term "receptor" refers to a chemical group in a molecule which comprises an active site in said molecule, or to an array of chemical groups in a molecule which comprise one or more active sites in said molecule, or to a molecule comprised of one or more chemical groups or one or more arrays of chemical groups, which group or groups or array of groups comprise one or more active sites in said molecule. An "active site" of a receptor has a specific capacity to bind to or has an affinity for binding to a ligand. With respect to use with the term "receptor" or with the term "active site in a receptor", the term "ligand" as used herein refers to a molecule comprised of a specific chemical group or a specific array of chemical groups which molecule, group, or array of groups is complementary to and has a specific affinity for binding to a receptor, especially to an active site in a receptor. Examples of receptors include enzymes which catalyze chemical reactions, and cell surface receptors which bind hormones and drugs. The sites of specific

10

15

20

25

30

35

binding of substrates for said enzymes and of hormones and drugs of said cell surface receptors are examples of active sites of said receptors, and the respective substrates, hormones, and drugs are examples of ligands for said receptors.

Preferred receptors (Rec) in System A and System B are comprised of the residue of an active site of an enzyme, and preferred ligands in System A and System B are comprised of the residue of a substrate for said active site of said enzyme.

An especially preferred receptor is comprised of the active site of any protein having dihydrofolate reductase (DHFR) activity. Said DHFR can be isolated, in whole or in part, from any source and used in this invention without further modification, or it can be chemically modified before or after isolation for use in this invention, or it can be modified by well known techniques of molecular biology and isolated for use in this invention, or said molecular biology modified DHFR can be chemically modified before or after isolation for use in this invention as long as the DHFR active site is maintained in such use.

According to the 1992 Sigma Chemical Company catalog on page 350, DHFR activity is defined in terms of units: one said unit of DHFR enzyme activity is defined as the amount of material needed to convert 1.0 micromole of 7,8-dihydrofolate and NADPH to 5,6,7,8-tetrahydrofolate and NADP per minute at pH 6.5 and 25°C. Thus, as used herein, a chemical species comprised of a group or array of groups that catalyze the conversion of 7,8-dihydrofolate and NADPH to 5,6,7,8-tetrahydrofolate and NADP has DHFR activity and such group or array of groups comprises a dihydrofolate reductase active site, i.e., a DHFR. In addition, the modification of a DHFR by known techniques of molecular biology or by chemical modification may reduce the protein's ability to

catalyze the conversion of 7,8-dihydrofolate and NADPH to 5,6,7,8-tetrahydrofolate and NADP yet retain the protein's capacity to bind a ligand.

Examples of ligands that have an affinity for binding to the active site in said DHFR include 7,8-dihydrofolate, derivatives and analogs of 7,8-dihydrofolate, and residues of said derivatives and analogs which may be agonists or antagonists of DHFR activity with respect to 7,8-dihydrofolate. Preferred examples of ligands which exhibit an affinity for binding to a DHFR are comprised of antifolate drugs as described in "Principals of Drug Action, The Basis of Pharmacology", Third Edition, Churchill Livingstone, New York, 1990, Pratt W. B. and Taylor P., Editors, page 623 which are antagonists of DHFR activity with respect to 7,8-dihydrofolate, and of inhibitors of DHFR activity as described in Blaney, J. M., Hansch, C., Silipo, C., and Vittoria, A., Chemical Reviews, (1984), Vol. 84, pp 333-407. Additional preferred examples are comprised of derivatives and analogs of said antifolate drugs and inhibitors, and residues of said derivatives and said analogs of said antifolate drugs and inhibitors.

Especially preferred ligands which exhibit an affinity for binding to a DHFR are comprised of residues of the antifolate drugs, pyrimethamine, methotrexate, tetroxoprim, and trimethoprim. Most preferred are comprised of residues of the antifolate drugs, methotrexate and trimethoprim.

In one aspect in System A and in System B, the DHFR is comprised of a non-human protein, preferably comprised of a bacterial or protozoal protein, and more preferably of a bacterial protein. Preferably, said DHFR is comprised of protein derived from *S. aureus* or from *E. Coli*. More preferably, said DHFR is comprised of protein derived from *E. Coli* (strain CV634) infected

with the plasmid pCV29 which harbors the *E. coli* DHFR gene.

In another aspect in System A and in System B, the DHFR is comprised of a human protein. Preferably, said DHFR is comprised of a recombinant human protein. More preferably, said DHFR is comprised of a recombinant human protein which is modified by genetic engineering techniques, which modifications comprise the independent incorporation, substitution, insertion, and deletion of specific amino acids in a peptide sequence of said protein. Yet more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to substrates, which affinity is greater than the affinity of natural human protein for said substrates. Even more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drugs, methotrexate and trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drugs. Most preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drug, trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drug.

In yet another aspect, the Z-L-X of System A is comprised of a fusion protein. As used herein, the term "fusion protein" refers to a genetically engineered material comprised of a protein whose coding region is comprised of the coding region of a residue of a first protein fused, in frame, to the coding region of a residue of a second protein. Preferably, said fusion protein is comprised of a protein whose coding region is

5 DHFR is comprised of a recombinant human protein. More preferably, said DHFR is comprised of a recombinant human protein which is modified by genetic engineering techniques, which modifications comprise the independent incorporation, substitution, insertion, and deletion of specific amino acids in a peptide sequence of said protein. Yet more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to substrates, which affinity is greater than the affinity of natural human protein for said substrates. Even more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drugs, methotrexate and trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drugs. Most preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drug, trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drug.

10 In yet another aspect, the Z-L-X of System A is comprised of a fusion protein. As used herein, the term "fusion protein" refers to a genetically engineered material comprised of a protein whose coding region is comprised of the coding region of a residue of a first protein fused, in frame, to the coding region of a residue of a second protein. Preferably, said fusion protein is comprised of a protein whose coding region is

15 DHFR is comprised of a recombinant human protein. More preferably, said DHFR is comprised of a recombinant human protein which is modified by genetic engineering techniques, which modifications comprise the independent incorporation, substitution, insertion, and deletion of specific amino acids in a peptide sequence of said protein. Yet more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to substrates, which affinity is greater than the affinity of natural human protein for said substrates. Even more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drugs, methotrexate and trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drugs. Most preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drug, trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drug.

20 In yet another aspect, the Z-L-X of System A is comprised of a fusion protein. As used herein, the term "fusion protein" refers to a genetically engineered material comprised of a protein whose coding region is comprised of the coding region of a residue of a first protein fused, in frame, to the coding region of a residue of a second protein. Preferably, said fusion protein is comprised of a protein whose coding region is

25 DHFR is comprised of a recombinant human protein. More preferably, said DHFR is comprised of a recombinant human protein which is modified by genetic engineering techniques, which modifications comprise the independent incorporation, substitution, insertion, and deletion of specific amino acids in a peptide sequence of said protein. Yet more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to substrates, which affinity is greater than the affinity of natural human protein for said substrates. Even more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drugs, methotrexate and trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drugs. Most preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drug, trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drug.

30 In yet another aspect, the Z-L-X of System A is comprised of a fusion protein. As used herein, the term "fusion protein" refers to a genetically engineered material comprised of a protein whose coding region is comprised of the coding region of a residue of a first protein fused, in frame, to the coding region of a residue of a second protein. Preferably, said fusion protein is comprised of a protein whose coding region is

35 DHFR is comprised of a recombinant human protein. More preferably, said DHFR is comprised of a recombinant human protein which is modified by genetic engineering techniques, which modifications comprise the independent incorporation, substitution, insertion, and deletion of specific amino acids in a peptide sequence of said protein. Yet more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to substrates, which affinity is greater than the affinity of natural human protein for said substrates. Even more preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drugs, methotrexate and trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drugs. Most preferably, the DHFR comprised of a thus modified recombinant human protein is comprised of an active site which has an affinity for binding to residues of the antifolate drug, trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residues of said antifolate drug.

comprised of the coding region of a residue of an immunoreactive reagent fused, in frame, to the coding region of one or more residues of a DHFR. Thus, preferably, said fusion protein is comprised of a residue of an immunoreactive reagent fused to one or more residues of a DHFR. In a preferred embodiment, said fusion protein is comprised of residues of DHFR fused to an immunoglobulin heavy chain in the CH₁ region, such that when combined with an appropriate light chain the said fusion protein comprises an Fab fragment linked to one or more DHFR. In another preferred embodiment, said fusion protein can be comprised of one or more DHFR fused to an immunoglobulin heavy chain in the CH₂ or in the CH₃ region. In yet another preferred embodiment, said fusion protein, when comprised of an immunoglobulin light chain, can be comprised of a Fab'2 fragment linked to one or more DHFR. In still another preferred embodiment, said fusion protein can be comprised of one or more DHFR fused to the C-terminal end of an immunoglobulin single-chain construct and thus be comprised of an Fv fragment linked to one or more DHFR.

the above genetically engineered human protein comprising Z-I-X of System A can be comprised a protein whose coding region is independently comprised of the coding region of a residue of a human or of a non-human first protein fused, in frame, to the coding region of a residue of a human or non-human second protein.

and bacterial or modified by genetic engineering techniques as above. More preferably, the fusion protein is comprised of a protein whose coding region is comprised of the coding region of a residue of a human immunoreactive reagent fused, in frame, to the coding region of one or more residues of a bacterial or human DHFR or a genetically engineered modified bacterial or human DHFR. Yet more preferably, the fusion protein is

comprised of a thus modified recombinant human DHFR comprised of an active site which has an affinity for binding to a ligand, which affinity is greater than the affinity of natural human protein for said ligand.

Even more preferably, the fusion protein is comprised of a thus modified recombinant human DHFR comprised of an active site which has an affinity for binding to a ligand comprised of a residue of an antifolate drug such as methotrexate or trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residue of said ligand.

Most preferably, the fusion protein is comprised of a thus modified recombinant human DHFR comprised of an active site which has an affinity for binding to a ligand comprised of a residue of trimethoprim, which affinity is greater than the affinity of natural human protein for binding to the residue of said ligand.

The binding of a ligand to a receptor can comprise the formation of a covalent bond or it can comprise a non-covalent interaction. Preferably, in this invention the binding of a ligand to a receptor comprises a non-covalent interaction, sometimes herein referred to as noncovalent binding.

In System A, the DHFR is covalently linked, i.e., conjugated, to an immunoreactive group, preferably to an antibody or to an antibody fragment, most preferably to ING-1, to form the NRTR [i.e., $Z-(Y-Rec)n$] of the System.

In System B, in one embodiment, the DHFR as a component of a radioactive delivery agent [i.e., an RDA, $Rec-[125I-Q-M]_n$] is attached to one or more chelating groups, each by means of a linking group, and the chelating group is associated with a radionuclide. Preferably the chelating group is TMT (described hereinbelow), the linking group is as described below, and the radionuclide is $131I$.

In System B, in one embodiment, the DEFR as a component of a radioactive delivery agent [i.e., an RDA, $\text{Rec-}(\text{Lz-O-M})_m$] is attached to one or more chelating groups, each by means of a linking group, and the chelating group is associated with a radionuclide. Preferably the chelating group is TMT (described hereinbelow), the linking group is as described below, and the radionuclide is 90Y .

30 35

23

In another embodiment, the RDA in System B is comprised of a DHFR that contains one or more radionuclides that are covalently attached, either directly to one or more components of the DHFR or to one or more components that are attached by a linking group as described below to the DHFR. Preferably, said covalently attached radionuclide is a radioisotope of iodine attached to an aromatic ring-containing moiety.

In another embodiment, the RDA in System B is comprised of a DHFR that contains one or more radionuclides that are covalently attached, either directly to one or more components of the DHFR or to one or more components that are attached by a linking group as described below to the DHFR. Preferably, said covalently attached radionuclide is selected from a radioisotope of technetium and rhenium attached to a group comprised of a sulfur atom.

In System A, chemical conjugation can be achieved, for example, by a technique comprising the use of a linking group (L_1) which is introduced through modification of, for example, a site on an immunoreactive group. The introduction of activated groups such as activated ethylene groups (e.g., maleimide groups) on to amine groups such as lysine epsilon-amines of a protein is represented in Scheme 1. Other techniques include the use of heterobifunctional linking moieties and chemical modifications such as the examples described in U. S. Patent No. 4,719,182. Additionally, those chemicals such as SMCC which are commonly commercially available, for example, from Pierce Chemical Company are included as non-limiting examples.

In both System A and System B in one aspect, chemical conjugation is otherwise achieved by using a linking group (L_1 and L_2 , respectively) which is introduced through mild reduction of the DHFR (or of the

24

DHFR modified by reagents which contain disulfide bonds) with a reducing reagent such as dithiothreitol to produce sulphydryl (SH) sites in the reduced DHFR protein moiety. In System A, addition of the thus reduced DHFR protein moiety to the above described maleimide modified antibody (Ab-M) results in an antibody/receptor conjugate (Ab-M-S-DHFR protein) linked together by one or more thioether bonds. Additionally, those chemicals which are commonly commercially available, for example, from Pierce Chemical Company and the like which are useful in the covalent attachment of two proteins are included as non-limiting examples in the coupling of DHFR to antibody in System A.

In System B, addition of the thus reduced DHFR protein moiety to a chelating agent which contains a precursor of a linking group comprised of an activated ethylene group such as a maleimide group results in a DHFR/chelating agent conjugate linked together by one or more thioether bonds. Similarly, addition of the thus reduced immunoreactive protein moiety to the residue of a ligand which contains a precursor of a linking group comprised of an activated ethylene group such as a maleimide group results in a immunoreactive protein moiety/ligand conjugate linked together by one or more thioether bonds.

In System A, other groups are useful in the coupling of the immunoreactive material to the receptor moiety, particularly if the above reagents are utilized. Suitable reactive sites on the immunoreactive material and on the receptor moiety include:

- amine sites of lysine;
- terminal peptide amines;
- carboxylic acid sites, such as are available in aspartic acid and glutamic acid;
- sulphydryl sites;
- carbohydrate sites;

activated carbon-hydrogen and carbon-carbon bonds which can react through insertion via free radical reaction or nitrene or carbene reaction of a so activated residue;

In System A, the ratio of DHFR to immunoreactive group such as an antibody can vary widely from about 0.5 to 10 or more. In bulk, mixtures comprised of immunoreactive groups which are unmodified and immunoreactive groups which are modified with DHFR are also suitable. Such mixtures can have a bulk ratio of DHFR to immunoreactive group of from about 0.1 to about 10.

In System A, in preferred embodiments, the mole ratio of DHFR to immunoreactive group is from about 1:1 to about 6:1. It is specifically contemplated that with knowledge of the DNA sequence that encodes DHFR, especially bacterial and human DHFR, a fusion protein can be made between the antibody and the DHFR, or portions thereof, through the use of genetic engineering techniques. It is specifically contemplated that in all of these compositions of DHFR bound to antibody, DHFR retains a capacity to bind to the ligands described in the invention.

In System B, the ratio of ligand to immunoreactive group such as an antibody can vary widely from about 0.5 to 10 or more. In bulk, mixtures comprised of immunoreactive groups which are unmodified and immunoreactive groups which are modified with ligand are also suitable. Such mixtures can have a bulk ratio of ligand to immunoreactive group of from about 0.1 to about 10. In preferred embodiments, the mole ratio of ligand to immunoreactive group is from about 1:1 to about 6:1.

In System A, following the linking of the immunoreactive group, preferably of an antibody or an antibody fragment, to DIFR, the conjugate is purified by passage of the material through a gel permeation column such as Superose 6 using an appropriate elution buffer or by elution from a HPLC column such as a Shodex WS-803F size exclusion column. Both these methods separate the applied materials by molecular size resulting in the elution of the antibody/DIFR conjugate in a different fraction from any residual non-conjugated DIFR.

5 In System A, the concentrations of the antibody in the conjugate solutions are determined by the Bradford (BioRad Catalog # 500-0001) method using bovine immunoglobulin as the protein standard.

In System B, following the linking of the immunoreactive group, preferably of an antibody or an antibody fragment, to the residue of a ligand, the conjugate is purified by passage of the material through a gel permeation column such as Superose 6 using an appropriate elution buffer or by elution from a HPLC column such as a Shodex WS-803F size exclusion column. Both these methods separate the applied materials by molecular size resulting in the elution of the antibody/ligand conjugate in a different fraction from any residual non-conjugated ligand.

10 In System B, the concentrations of the antibody in the conjugate solutions are determined by the BioRad protein assay using bovine immunoglobulin as the protein standard.

15 In System A, the ability of the antibody to bind its target antigen following conjugation to DIFR can be assayed by ELISA or flow cytometry. A 30 cm x 7.5 mm TSK-G3000SW size-exclusion HPLC column (Sugelco) fitted with a guard column of the same material can be used to determine the amount of aggregation in the final conjugate.

20

25

30

35

In System B, the ability of the antibody to bind to its target antigen following conjugation to the residue of a ligand can be assayed by ELISA or flow cytometry. A 30 cm x 7.5 mm TSK-G3000SW size-exclusion HPLC column (Supelco) fitted with a guard column of the same material can be used to determine the amount of aggregation in the final conjugate.

In System A, the dihydrofolate reductase enzymic activity of the antibody-associated DHFR can be assayed by following the oxidation of pyridine nucleotides during the reduction of folate to tetrahydrofolate by DHFR as described by Mathews and Hennetens (J. Biol. Chem. 238, 3436-3442 (1963)). This method can also be used to assay the DHFR inhibitory effects of the novel DHFR binding ligands which are modified to include chelating agents as described in this invention.

In System B, the dihydrofolate reductase enzymic activity of the chelating agent-associated DHFR can be assayed by following the oxidation of pyridine nucleotides during the reduction of folate to tetrahydrofolate by DHFR as described by Mathews and Hennetens (J. Biol. Chem. 238, 3436-3442 (1963)).

This method can also be used to assay the DHFR inhibitory effects of the novel ligands which have an affinity for binding to DHFR and which are linked to immunoreactive groups as described in this invention. L1 and L2 in System A and System B are independently a chemical bond or the residue of a linking group. In one aspect, the phrase "residue of a linking group" as used herein refers to a moiety that remains, results, or is derived from the reaction of a protein reactive group with a reactive site on a protein. The phrase "protein reactive group" as used herein refers to any group which can react with functional groups typically found on proteins. However, it is specifically contemplated that such protein

reactive groups can also react with functional groups typically found on relevant nonprotein molecules. Thus, in one aspect the linking groups L1 and L2 useful in the practice of this invention derive from those groups which can react with any relevant molecule "Z" or "Rec" as described above containing a reactive group, whether or not such relevant molecule is a protein, to form a linking group. In one aspect, preferred linking groups thus formed include the linking group, L1, between the immunoreactive group, "Z", and the DHFR active site containing species, "Rec", in the NRTR System A; the linking group, L1, between the immunoreactive group, "Z", and DHFR ligand species (e.g., "TMP" or "MTX") in the NRTR in System B; and the linking group, L2, between the DHFR active site containing species, "Rec", and the chelating agent, "Q", in the RDA in System B; and between the DHFR ligand species (e.g., "TMP" or "MTX") and the chelating agent, "Q", in the RDA in System A.

Preferred linking groups are derived from protein reactive groups selected from but not limited to:

- (1) a group that will react directly with amine, alcohol, or sulfhydryl groups on the immunoreactive protein or biological molecule containing the reactive group, for example, active halogen containing groups including, for example, chloromethylphenyl groups and chloroacetyl [ClCH₂C(=O)-] groups, activated 2-(leaving group substituted)-ethylsulfonyl and ethylcarbonyl groups such as 2-chloroethylsulfonyl and ethylcarbonyl chloroethylcarbonyl; vinylsulfonyl; vinylcarbonyl; epoxy; isocyanato; aldehyde; aziridino; succinimidoylcarbonyl; activated acyl groups such as carboxylic acid halides; mixed anhydrides and the like; and other groups known to be useful in conventional photographic gelatin hardening agents;

(2) a group that can react readily with modified proteins or biological molecules containing the immunoreactive group, i.e., proteins or biological molecules containing the immunoreactive group modified to contain reactive groups such as those mentioned in (1) above, for example, by oxidation of the protein to an aldehyde or a carboxylic acid, in which case the "linking group" can be derived from protein reactive groups selected from amino, alkylamino, arylamino, hydrazino, alkylhydrazino, arylhydrazino, carbazido, semicarbazido, thiocarbazido, thiosemicarbazido, sulfhydryl, sulfhydrylalkyl, sulphydrylaryl, hydroxy, carboxy, carboxyalkyl and carboxyaryl. The alkyl portions of said linking groups can contain from 1 to about 20 carbon atoms. The aryl portions of said linking groups can contain from about 6 to about 20 carbon atoms; and

(3) a group that can be linked to the protein or biological molecule containing the immunoreactive group or to the modified protein as noted in (1) and (2) above by use of a crosslinking agent. The residues of certain useful crosslinking agents, such as, for example, homoifunctional and heterobifunctional gelatin hardeners, bisepoxides, and bisisocyanates can become a part of, i.e., a linking group in, for example, the protein-(DHEP active site-containing species) conjugate in System A during the crosslinking reaction. Other useful crosslinking agents, however, can facilitate the crosslinking, for example, as consumable catalysts, and are not present in the final conjugate. Examples of such crosslinking agents are carbodiimide and carbamoylonium crosslinking agents as disclosed in U.S. Patent No. 4,121,847 and the ethers of U.S. Patent No. 4,877,724. With these crosslinking agents, one of the reactants such as the immunoreactive group must have a carboxyl group and the other such as the oligonucleotide

containing species must have a reactive amine, alcohol, or sulfhydryl group. In amide bond formation, the crosslinking agent first reacts selectively with the carboxyl group, then is split out during reaction of the thus "activated" carboxyl group with an amine to form an amide linkage between, for example, the protein and DHEA active site containing species, thus covalently bonding the two moieties. An advantage of this approach is that crosslinking of like molecules, e.g., proteins with proteins or DHEA active site containing species with themselves is avoided, whereas the reaction of, for example, homo-bifunctional crosslinking agents is nonselective and unwanted crosslinked molecules are obtained.

Preferred useful linking groups are derived from various heterobifunctional cross-linking reagents such as those listed in the Pierce Chemical Company Immunotechnology Catalog - Protein Modification Section (1991 and 1992). Useful non-limiting examples of such reagents include:

Sulfo-SNCC	Sulfo-SNCC Shifosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate.
Sulfo-STAB	SulfoSTAB Sulfosuccinimidyl 4-(iodoacetyl) aminobenzoate.
Sulfo-SRPB	SulfoSRPB Sulfosuccinimidyl 4-(N-maleimidophenyl)butyrate.
2-IT	2-Iminothiolane.

N-Succinimidyl S-acetylthioacetate.

2-11

In addition to the foregoing description, the linking groups, in whole or in part, can also be comprised of and derived from complementary sequences of nucleotides and residues of nucleotides, both naturally occurring and modified, preferably non-self-associating oligonucleotide sequences. Particularly useful, non-limiting reagents for incorporation of modified nucleotide moieties containing reactive functional groups, such as amine and sulphydryl groups, into an oligonucleotide sequence are commercially available from, for example, Clontech Laboratories Inc. (Palo Alto, California) and include Uni-Link AmidoModifier (Catalog # 5190), Biotin-ON Phosphoramidite (Catalog # 5191), N-MNT-C6-Aminomodifier (Catalog # 5202), Aminomodifier II (Catalog # 5203), DMT-C6-3'Amine-ON (Catalog # 5222), C6-ThioldModifier (Catalog # 5211), and the like. In one aspect, linking groups of this invention are derived from the reaction of a reactive functional group such as an amine or sulphydryl group as are available in the above Clontech reagents, one or more of which has been incorporated into an oligonucleotide sequence, with, for example, one or more of the previously described protein reactive groups such as heterobifunctional protein reactive groups, one or more of which has been incorporated into, for example, an immune reactive agent or DHFR active site containing moiety of this invention.

In the NRTR of System A, complementary oligonucleotide sequences are attached to two components of the conjugate, respectively, one sequence to the immune reactive agent and the complementary oligonucleotide sequence to the DHFR active site containing moiety. The hybrid formed between the two complementary oligonucleotide sequences then comprises the linking group between the immune reactive agent and the DHFR active site containing moiety.

In the RDA of System B, the complementary oligonucleotide sequences are attached to two components of the conjugate, one sequence to the residue comprised of one or more chelating agents and the complementary oligonucleotide sequence to the DHFR active site containing moiety. The hybrid formed between the two complementary oligonucleotide sequences then comprises the linking group between the DHFR active site containing moiety and the component comprised of one or more chelating agents.

In System B, of course, two or more copies of the same oligonucleotide sequence can be linked, for example, in tandem to one DHFR active site containing moiety and a complementary oligonucleotide sequence comprised of multiple chelating agents can be added. The multiple hybrids formed between the two complementary oligonucleotide sequences then comprises the linking group between the DHFR active site containing moiety and multiple chelating agents.

Likewise, in System B, the residue of one or more ligands which have an affinity for non-covalent binding to DHFR can be attached to the immunoreactive group using complementary oligonucleotide hybrids as described above.

In System A, analogously, multiple DHFR sequences can be attached to the immunoreactive protein. Likewise, in System A, one or more ligands which have an affinity for non-covalent binding to DHFR can be attached to multiple chelating agents using complementary oligonucleotide hybrids as described above.

Q in System A and in System B represents the residue of a chelating group. The chelating group of this invention can comprise the residue of one or more of a wide variety of chelating agents that can have a radionuclide associated therewith. As is well known, a

chelating agent is a compound containing donor atoms that can combine by coordinate bonding with a metal atom to form a cyclic structure called a chelation complex or chelate. This class of compounds is described in the Kirk-Othmer Encyclopedia of Chemical Technology, Vol. 5, 339-368.

The residues of suitable chelating agents can be independently selected from polyphosphates, such as sodium tripolyphosphate and hexametaphosphoric acid; aminocarboxylic acids, such as ethylenediaminetetraacetic acid, N-(2-hydroxyethyl)ethylene-diaminetetraacetic acid, nitrilotriacetic acid, N,N-di(2-hydroxyethyl)glycine, ethylenebis(hydroxyphenylglycine) and diethylenetriamine pentacetic acid; 1,3-diketones, such as acetylacetone, trifluoroacetylacetone, and thenoyltrifluoroacetone; hydroxycarboxylic acids, such as tartaric acid, citric acid, gluconic acid, and 5-sulfosalicylic acid; polyamines, such as ethylenediamine, diethylenetriamine, triethylenetriamine, and triaminotriethylamine; aminoalcohols, such as triethanolamine and N-(2-hydroxyethyl)ethylene-diamine; aromatic heterocyclic bases, such as 2,2'-dipyridyl, 2,2'-dilimidaole, dipicoline amine and 1,10-phenanthroline; phenols, such as salicylaldehyde, disulopyrocatechol, and chromotropic acid; aminophenols, such as 8-hydroxyquinoline and oximesulfonic acid; oximes, such as dimethylglyoxime and salicylaldoxime; peptides containing proximal chelating functionality such as polycysteine, polyhistidine, polyaspartic acid, polyglutamic acid, or combinations of such amino acids; Schiff bases, such as disalicylaldehyde 1,2-propylenediamine; tetrapyrroles, such as tetraphenylporphyrin and phthalocyanine; sulfur compounds, such as toluenedithiol, meso-2,3-dimercaptosuccinic acid, dimercapropanol, thioglycolic acid, potassium

ethyl xanthate, sodium diethylthiocarbamate, dithizone, diethyl dithiophosphoric acid, and thiourea; synthetic macrocyclic compounds, such as dibenzo[18]crown-6, (CH₃)₆-[14]-4,11-diene-N₄, and (2,2'-cryptate); and phosphonic acids, such as nitrilotriethylene-phosphonic acid, ethylenediaminetetra(methylene-phosphonic acid), and hydroxyethylidenediphosphonic acid, or combinations of two or more of the above agents.

Preferred residues of chelating agents contain polycarboxylic acid groups and include: ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DO3A); 1-oxa-4,7,10-triazaacyclododecane-N,N',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).

Preferred residues of chelating agents contain polycarboxylic acid groups and include: B4A, P4A, TMT, DCDTPA, PheMT, macroPheMT, and macroTMT;

5 ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).

10 Preferred residues of chelating agents contain polycarboxylic acid groups and include: B4A, P4A, TMT, DCDTPA, PheMT, macroPheMT, and macroTMT;

15 ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).


20 Preferred residues of chelating agents contain polycarboxylic acid groups and include: B4A, P4A, TMT, DCDTPA, PheMT, macroPheMT, and macroTMT;

25 ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).

30 ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).

35 ethylenediamine-N,N',N'',N'''-tetraacetic acid (EDTA); N,N,N',N'',N'''-diethylenetriaminepentaacetic acid (DTPA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (DOTA); 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-triacetic acid (ORTA); and trans(1,2)-cyclohexanodimethylenetriamine pentaacetic acid (CDTPA).

35



36

Other suitable residues of chelating agents are described in PCT/US91/08253, the disclosure of which is hereby incorporated by reference. If Q is comprised of the residue of multiple chelating agents, such agents can be linked together by one or more linking groups such as described above.

The residues of the chelating agent Q are independently linked to the other components of this invention through a chemical bond or a linking group such as L₂ as described above. Preferred linking groups also include nitrogen atoms in groups such as amino, imido, nitrilo and imino groups; alkylene, preferably containing from 1 to 18 carbon atoms such as methylene, ethylene, propylene, butylene and hexylene, such alkylene optionally being interrupted by 1 or more heteroatoms such as oxygen, nitrogen and sulfur or heteroatom-containing groups; carbonyl; sulfonyl; sulfinyl; ether; thioether; ester, i.e., carbonyloxy and oxycarbonyl; thioester, i.e., carbonylthio, thiocarbonyl, thiocarbonyloxy, and oxythiocarboxy; amide, i.e., iminocarbonyl and carbonylimino; thioamide, i.e., iminothiocarbonyl and thiocarbonylimino; thiodithio; phosphate; phosphonate; urelene; thiourethane; urethane, i.e., iminocarbonyloxy, and oxy carbonylimino; an amino acid linkage, i.e., a

or group wherein k=1 and X₁, X₂, X₃ independently are H, alkyl, containing from 1 to 18, preferably 1 to 6 carbon atoms, such as methyl, ethyl and propyl, such alkyl optionally being interrupted by 1 or more heteroatoms such as oxygen, nitrogen and sulfur, substituted or unsubstituted aryl, containing from 6 to 18, preferably 6 to 10 carbon atoms such as phenyl, hydroxyiodophenyl,

5

10

15

20

25


30

In one aspect, other suitable residues of chelating agents are comprised of proteins modified for the chelation of metals such as technetium and rhodium as described in U.S. Patent No. 5,078,985, the disclosure of which is hereby incorporated by reference.

In another aspect, suitable residues of chelating agents are derived from N₃S and N₂S₂ containing compounds, as for example, those disclosed in U.S. Patent Nos. 4,444,690; 4,670,545; 4,673,562; 4,897,255; 4,965,392; 4,980,147; 4,988,496; 5,021,556 and 5,075,099.

37

hydroxyphenyl, fluorophenyl and naphthyl, aralkyl, preferably containing from 7 to 12 carbon atoms, such as benzyl, heterocycl, preferably containing from 5 to 7 nuclear carbon and one or more heteroatoms such as S, N, P or O, examples of preferred heterocycl groups being pyridyl, quinolyl, imidazolyl and thiényl; heterocyclalkyl, the heterocycl and alkyl portions of which preferably are described above; or a peptide linkage, i.e., a



5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

1690

1695

1700

1705

1710

1715

1720

1725

1730

1735

1740

1745

1750

1755

1760

1765

1770

1775

1780

1785

1790

1795

1800

1805

1810

1815

1820

1825

1830

1835

1840

1845

1850

1855

1860

1865

1870

1875

1880

1885

1890

1895

1900

1905

1910

1915

1920

1925

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

2010

2015

2020

2025

2030

2035

2040

2045

2050

2055

2060

2065

2070

2075

2080

2085

2090

2095

2100

2105

2110

2115

2120

2125

2130

2135

2140

2145

2150

2155

2160

2165

2170

2175

2180

2185

2190

2195

2200

2205

2210

2215

2220

2225

2230

2235

2240

2245

2250

2255

2260

2265

2270

2275

2280

2285

2290

2295

2300

2305

2310

2315

2320

2325

2330

2335

2340

2345

2350

2355

2360

2365

2370

2375

2380

2385

2390

2395

2400

2405

2410

2415

2420

2425

2430

2435

2440

2445

2450

2455

2460

2465

2470

2475

2480

2485

2490

2495

2500

2505

2510

2515

2520

2525

2530

2535

2540

2545

2550

2555

2560

2565

2570

2575

2580

2585

2590

2595

2600

2605

2610

2615

2620

2625

2630

2635

2640

2645

2650

2655

2660

2665

2670

2675

2680

2685

2690

2695

2700

2705

2710

2715

2720

2725

2730

2735

2740

2745

2750

2755

2760

2765

2770

2775

2780

2785

2790

2795

2800

2805

2810

2815

2820

2825

2830

2835

2840

2845

2850

2855

2860

2865

2870

2875

2880

2885

2890

2895

2900

2905

2910

2915

2920

2925

2930

2935

2940

2945

2950

2955

2960

2965

2970

2975

2980

2985

2990

2995

3000

3005

3010

3015

3020

3025

3030

3035

3040

3045

3050

3055

3060

3065

3070

3075

3080

3085

3090

3095

3100

3105

3110

3115

3120

3125

3130

3135

3140

3145

3150

3155

3160

3165

3170

3175

3180

3185

3190

3195

3200

3205

3210

3215

3220

3225

3230

3235

3240

3245

3250

3255

3260

3265

3270

3275

3280

3285

3290

3295

3300

3305

3310

3315

3320

3325

3330

3335

3340

3345

3350

3355

3360

3365

3370

3375

3380

3385

3390

3395

3400

3405

3410

3415

3420

3425

3430

3435

3440

3445

3450

3455

3460

3465

3470

3475

3480

3485

3490

3495

3500

3505

3510

3515

3520

3525

3530

3535

3540

3545

3550

3555

3560

3565

3570

3575

3580

3585

3590

3595

3600

3605

3610

3615

3620

3625

3630

3635

3640

3645

3650

3655

3660

3665

3670

3675

3680

3685

3690

3695

3700

3705

3710

3715

3720

3725

3730

3735

3740

3745

3750

3755

3760

3765

3770

3775

3780

3785

3790

3795

3800

3805

3810

3815

3820

3825

3830

3835

3840

3845

3850

3855

3860

3865

3870

3875

3880

3885

3890

3895

3900

3905

3910

3915

3920

3925

3930

3935

3940

3945

3950

3955

3960

3965

3970

3975

3980

3985

3990

3995

4000

4005

4010

4015

4020

4025

4030

4035

4040

4045

4050

4055

4060

4065

4070

4075

4080

4085

4090

4095

4100

4105

4110

4115

4120

4125

4130

4135

4140

4145

4150

4155

4160

4165

4170

4175

4180

4185

4190

4195

4200

4205

4210

4215

4220

4225

4230

4235

4240

4245

4250

4255

4260

4265

4270

4275

4280

4285

4290

4295

4300

4305

4310

4315

4320

4325

4330

4335

4340

4345

4350

4355

4360

4365

4370

4375

4380

4385

4390

4395

4400

4405

4410

4415

4420

4425

4430

4435

4440

4445

4450

4455

4460

4465

4470

4475

4480

4485

4490

4495

4500

4505

4510

4515

4520

4525

4530

4535

4540

4545

4550

4555

4560

4565

4570

4575

4580

4585

4590

4595

4600

4605

4610

4615

4620

4625

4630

4635

4640

4645

4650

4655

4660

4665

4670

4675

4680

4685

4690

4695

4700

4705

4710

4715

4720

4725

4730

4735

4740

4745

4750

4755

4760

4765

4770

4775

4780

4785

4790

4795

4800

4805

4810

4815

4820

4825

4830

4835

4840

4845

4850

4855

4860

4865

4870

4875

4880

4885

4890

4895

4900

4905

4910

4915

4920

4925

4930

4935

4940

4945

4950

4955

4960

4965

4970

4975

4980

4985

4990

4995

5000

5005

5010

5015

5020

5025

5030

5035

5040

5045

5050

5055

5060

5065

5070

5075

5080

5085

5090

5095

5100

5105

5110

5115

5120

5125

5130

5135

5140

5145

5150

5155

5160

5165

5170

5175

5180

5185

5190

5195

5200

5205

5210

5215

5220

5225

5230

5235

5240

5245

5250

5255

5260

5265

5270

5275

5280

5285

5290

5295

5300

5305

5310

5315

5320

5325

5330

5335

5340

5345

5350

5355

5360

5365

5370

5375

5380

5385

5390

5395

5400

5405

5410

5415

5420

5425

5430

5435

5440

5445

5450

5455

5460

5465

5470

5475

5480

5485

5490

5495

5500

5505

5510

5515

5520

5525

5530

5535

5540

5545

5550

5555

5560

5565

5570

5575

5580

5585

5590

5595

5600

5605

5610

5615

5620

5625

5630

5635

5640

5645

5650

5655

5660

5665

5670

5675

5680

5685

5690

5695

5700

5705

5710

5715

5720

5725

5730

5735

5740

5745

5750

5755

5760

5765

5770

5775

5780

5785

5790

5795

5800

5805

5810

5815

5820

5825

5830

5835

5840

5845

5850

5855

5860

5865

5870

5875

5880

5885

5890

5895

5900

5905

5910

5915

5920

5925

5930

5935

5940

5945

5950

5955

5960

5965

5970

5975

5980

5985

5990

5995

6000

6005

6010

6015

6020

6025

6030

6035

6040

6045

6050

6055

6060

6065

6070

6075

6080

6085

6090

6095

6100

6105

6110

6115

6120

6125

6130

6135

6140

6145


6150

6155


616

41

SCHEME 3



SCHEME 4




42

43

In Systems A and B, specific examples of ligands

that have an affinity for non-covalent binding to a DHFR active site useful in this invention include residues of trimethoprim analogs and methotrexate analogs listed in Rahman et al., Methotrexate and Its Analogs; Medicinal Research Reviews, Vol. 8, No. 1, 95-157, and Kuyper et al., Carbonylsubstituted Trimethoprim Analogs; J. Med. Chem. Vol. 28, 303, (1985). Preferred analogs include those defined in structure (1) and in structure (1i), each comprising a reactive group to permit or facilitate binding of one portion of the ligand to the immunoreactive species, Z, in System B and to the chelating agent, Q, in System A.

Ligands comprised of trimethoprim analogs that are useful in the practice of this invention include derivatives defined in structure (1) above where: R₁, R₂, and R₃ are independently selected from H, alkyl (such as methyl) as a preferred group for one or two of R₁, R₂, and R₃, aralkyl, aryl (including substituted aryl), an alkylene carboxylic acid or amide derivative thereof, an alkylene group that contains one or more heteroatoms (such as, but not limited to, for example, oxygen [as an ether or a hydroxyl group] or sulfur [as a thioether group]), an amino acid group and a peptide group, and at least one of -R₁, -R₂, and -R₃ is of the form represented in structure 13:



30

radiolotope, M, of a metal ion such as yttrium, indium, rhenium, copper, scandium, bismuth, lead, or lutetium

wherein:

X is an alkylene group from 1 to 12 carbon atoms which may contain one or more heteroatoms such as oxygen, sulfur or nitrogen; L is a linking group as defined above, preferably the residue of an amide group, a chemical bond, an amino acid residue, or an arylene group which may be substituted by one or more hydroxyl groups; A is an alkylene group, a polyalkylene oxydyl group, an amino acid residue, a peptide residue, X, or a group containing pendant substituents which contain heteroatoms (such as, for example, oxygen in the form of one or more hydroxyl groups, carboxylic acid groups or salts thereof, amido groups, ether groups, sulfur in the form of thioether, sulfone, sulfoxide or sulfonate, nitrogen in the form of amino groups, amido groups or a diazo linkage, or phosphorous in the form of phosphate); B is selected from A but modified to contain one or more radionuclides bound thereto by chelating groups, Q, as defined above, such as, for example, but not limited to, TMT groups or DTPA groups, macrocyclic chelating groups, chelate groups that contain sulfur atoms, chelate groups that contain nitrogen atoms, chelate groups that contain pyridine rings, and chelate groups that contain carboxylate or phosphate groups; W is selected from H, alkyl, aralkyl, alkylene, carboxylic acid groups, amino groups, amido groups, aryl groups, hydroxaryl groups, a therapeutically effective and diagnostically effective radiolotope or an atom (such as iodine and the like) that can be covalently attached to a component of structure (1) [as distinct from a therapeutically effective or diagnostically effective radiolotope of an ion that can be bound to a component of structure (1) via a chelate group], a chelate group that may contain a

44

therapeutically effective or diagnostically effective structure (1) [as distinct from a therapeutically effective or diagnostically effective radiolotope of an ion that can be bound to a component of structure (1) via a chelate group], a chelate group that may contain a

and the like; x and v are independently zero or one; a is zero or an integer from one to about 100; b , q , and f are independently integers from one to about 100.

In the RDA of System A, a preferred non-limiting example of a linking group includes the residue of a protected (D)-Glu-(Ala)⁴-Lys-Lys (4) as well as the residue of a protected (L)-Glu-(Ala)⁴-(Lys)₂. Both 4'-carboxymethyl-Lys-trimethoprim (structure 5) and

methotrexate analog (structure 11a) undergo coupling reactions (see SCHEMES 2, 3 and 4) followed by deprotection to afford trimethoprim-(D)-Glu-(Ala)⁴-Lys-Lys (structure 11i) and methotrexate (structure 11v) and the analogous L-Glu containing species, respectively. The synthetic schemes (2,3,4) describe the synthetic methods for trimethoprim-heptapeptide (structure 11i) and methotrexate-heptapeptide (structure 11v). Thus, the t-butoxycarbonyl (tBoc) blocked Lys-Lys (structure 2) is prepared using a dehydrative coupling method, for example, using DCC (dicyclohexylcarbodiimide) and two protected lysine groups (SCHEME 2). The FMOC (9-Fluorenylmethoxycarbonyl) group of Lys-Lys is then removed via base treatment, and 4 units of alanine are introduced as shown in SCHEME 2 to afford the blocked Ala-Ala-Ala-Ala-Lys-Lys (structure 3). After adding t-buty1 (tBu) blocked D-Glu on the N-terminal of the hexapeptide (structure 3), the resulting heptapeptide (structure 4) is coupled with 4'-carboxymethyl-Lys-trimethoprim (structure 5) to yield trimethoprim-heptapeptide (structure 6). The acidic deblocking of the peptide (structure 6) affords the desired trimethoprim-D-Glu-(Ala)⁴-Lys-Lys (structure 7).

30 trimethoprim-D-Glu-(Ala)⁴-Lys-Lys (structure 7) upon treatment with TMT-NCS (structure 8) (SCHEME 3) yields a

desirable ligand-to-chelating agent conjugate, trimethoprim-D-Glu-(Ala)⁴-(Lys-(TMT))-Lys-(TMT)],

(structure 9). A solution of trimethoprim-D-Glu-(Ala)⁴-

[Lys-(TMT)]-[Lys-(TMT)] (structure 9) in deionized water buffered with 0.5 M sodium acetate at a pH of about 6.0 at room temperature is treated with an aqueous HCl solution of 90% NaCl_3 to afford a radionuclide labeled (90%) trimethoprim-D-Glu-(Ala)⁴-(Lys-(TMT))-Lys-(TMT).

Employing the similar synthetic methods, but using a blocked L-Glu derivative, the analogous L-Glu-trimethoprim derived materials are obtained.

Employing the similar synthetic methods, a coupling reaction (Scheme 4) of the heptapeptide (structure 4) and the benzoic acid derivative, 4'-carboxy-methotrexate (structure 11a), yields the desired blocked methotrexate-D-Glu-(Ala)⁴-Lys-Lys (structure 10).

methotrexate-heptapeptide (structure 11), is obtained from acid deblocking of (structure 10), and reacts with TMT-NCS to afford the desirable methotrexate-D-Glu-(Ala)⁴-(Lys-(TMT))-Lys-(TMT) (structure 12). A solution of methotrexate-D-Glu-(Ala)⁴-(Lys-(TMT))-Lys-(TMT) (structure 12) in deionized water buffered with 0.5 M sodium acetate at a pH of about 6.0 at room temperature is treated with an aqueous HCl solution of 90% NaCl_3 to afford a radionuclide labeled (90%) methotrexate-D-Glu-(Ala)⁴-(Lys-(TMT))-Lys-(TMT).

Employing the similar synthetic methods, but using a blocked L-Glu derivative, the analogous L-Glu-methotrexate derived materials are obtained.

Racemic mixtures of D and L enantiomers of the above described trimethoprim and methotrexate derivatives are also useful in this invention.


Additional chelating agents and radionuclides bound to chelating agents are incorporated by preparing, for example, analogous peptides comprised of additional Lys-TMT and Lys-TMT-radionuclide groups. Preferably, the number of such Lys-TMT and Lys-TMT-radionuclide residues is from 1 to about 6, and more preferably from 2 to about 6.

paramagnetic element can be selected from elements of atomic number 21 to 29, 43, 44 and 57 to 71. The following elements are preferred: Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu. Mn, Gd, and Dy are especially preferred.


An example of a structure of an RDA that has utility in this invention is structure (1) above wherein R_1 , R_2 , and R_3 are as defined above and preferably wherein one of R_1 , R_2 , and R_3 is represented by structure 14.

paramagnetic element can be selected from elements of atomic number 21 to 29, 43, 44 and 57 to 71. The following elements are preferred: Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu. Mn, Gd, and Dy are especially preferred.

An example of a structure of an RDA that has utility in this invention is structure (i) above wherein R_1 , R_2 , and R_3 are as defined above and preferably wherein one of R_1 , R_2 , and R_3 is represented by structure 14.



CC(=S)NCCOC



14

where: R' and R" are selected from components of amino acids that comprise, for example, natural amino acids such as glycine, alanine, leucine, serine, lysine, isoleucine, glutamine, aspartic acid, glutamic acid, proline, threonine, valine, phenylalanine, tyrosine, a the like, as well as unnatural amino acids and racemates.

An example of a structure of an RDA that has utility in this invention is structure (i) above wherein R_1 , R_2 , and R_3 are as defined above and preferably wherein one of R_1 , R_2 , and R_3 is represented by structure 14.

independently selected from zero and an integer between 1 and 10 with the proviso that m_2 is at least 1, and preferably 2 to about 5; and


W is selected from OH, NH₂, a residue of THF, an O-alkyl group such as an O-methyl group, and NR₂Pb wherein R₂Pb are independently selected from alkyl groups such as methyl groups, H, and a polyalkylene oxidyl moiety such as as PEG-OH and PEG-O-alkyl (e.g., PEG-O-CH₃) with the PEG having an average molecular weight in the range between 45 and 5,000 daltons.

Another example of a structure that has utility in this invention is structure (1) above wherein R₁, R₂, and R₃ are as defined above and preferably wherein one of R₁, R₂, or R₃ is represented by structure 15.

۳

15

51



wherein: R' and R" are selected from components of amino acids that comprise, for example, natural amino acids such as glycine, alanine, leucine, serine, lysine, isoleucine, glutamine, aspartic acid, glutamic acid, proline, threonine, valine, phenylalanine, tyrosine, and the like, as well as unnatural amino acids or racemates of natural amino acids, and R' and R" can be independently selected from H, a polyalkylene oxidyl group, a branched peptide group which may contain one to about 10 additional chelate groups such as TMT; m₅ is an integer between 1 and 10, m₆, m₇, and m₉ are independently selected from zero and an integer between 1 and 10 with the proviso that m₇ is at least 1, and preferably 2 to about 5; W is selected from OH, NH₂, a TMT moiety, an O-alkyl group such as an O-methyl group, NR₂Rb wherein R₂Rb are independently selected from alkyl groups such as methyl, H, a polyalkylene oxide moiety such as PEG-OH and PEG-O-alkyl (e.g., PEG-O-CH₃) with the PEG having molecular weight in the range between 45 and 5,000 daltons; m₉ is selected from zero and an integer from 1 to about 12; and R' is selected from H and the residue of a TMT moiety with or without a radionuclide, said TMT moiety being linked via a thiourea group.

10 In another embodiment of this invention, an RDA comprised of at least two metal ions in combination with one another in the same formulation is specifically contemplated. For example, the use of a therapeutically effective dose of a radionuclide such as ⁹⁰Y+3 together with a diagnostic imaging effective dose of a paramagnetic ion such as Gd³⁺, the ratio of the molar concentration of the diagnostic imaging effective ion to the molar concentration of the radionuclide ion being typically greater than one, in a pharmaceutically effective formulation of said RDA permits the simultaneous magnetic resonance imaging of at least a portion of the tissue of a host patient during therapeutic treatment of said patient.

15 In another embodiment of this invention, the use of radioisotopes of iodine is specifically contemplated. For example, if the RDA of System A or of System B is comprised of substituents that can be chemically substituted by iodine in a covalent bond forming reaction, such as, for example, substituents containing hydroxylphenyl functionality, such substituents can be labeled by methods well known in the art with a radioisotope of iodine. The thus covalently linked

20

25

30

35

iodine species can be used in the aforementioned fashion in therapeutic and diagnostic imaging applications.

In a preferred embodiment, an effective dose of an RDA of System A or of System B as described above in a pharmaceutically acceptable medium is prepared by exposing a composition of a precursor of an RDA (said precursor being comprised of a residue of a ligand that has an affinity for non-covalent binding to a DHFR active site, a linking group, and a residue of a chelating agent in System A and of a residue of a DHFR active site, a linking group, and a residue of a chelating agent in System B) to a composition containing a radioactive metal ion such that the molar amount of said radionuclide metal ion is less than the molar amount of the chelating groups comprising the RDA in said composition, said duration of exposure lasting an effective time to permit uptake of said metal ion into said RDA.

In a preferred embodiment, an effective dose of a NTRIR of System A or System B as described above in a pharmaceutically acceptable medium is administered to a patient and said NTRIR is allowed to accumulate at the target site such as at a tumor site in said patient. Subsequently, at an effective time, an effective dose of a RDA as described above in a pharmaceutically acceptable medium is administered to said patient, and said RDA is allowed to accumulate at the target site, said target site being the said NTRIR accumulated at said tumor site in said patient.

In a preferred embodiment, a therapeutically effective dose of a NRTIR of System A or System B as described above in a pharmaceutically acceptable medium is administered to a patient or to a tissue from a patient and said NRTIR is allowed to accumulate at the target site such as at a tumor site in said patient. Subsequently, at a therapeutically effective time, a

the therapeutically effective dose of a RDA as described above in a pharmaceutically acceptable medium is administered to said patient, and said RDA is allowed to accumulate at the target site, said target site being the said NRTIR accumulated at said tumor site in said patient.

The present invention also comprises one or more **ENTNITIR** as described above formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection for oral administration in solid or liquid form, for rectal or topical administration, or the like. The present invention also comprises one or more **RDA** as described above formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection, for oral administration in solid or liquid form, for rectal, or topical administration, or the like.

The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenous, by intramuscularly or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravescically, locally (powders, ointments or drops), or as a buccal or nasal spray. It is specifically contemplated that the NRTIR and the FDA can be administered by the same route such as orally, rectally, parenterally (intravenous, by intramuscularly or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravescically, locally (powders, ointments or drops), or as a buccal or nasal spray. It is also contemplated that the NRTIR can be administered by a route different from that of the RDA.

55

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

10 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

15 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agaragar,

56

calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

10 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like. Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes.

15 The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceuticaly acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, stabilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl

5

solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

20 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

25 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agaragar,

10

solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

15 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

20 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agaragar,

15

solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

25 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

30 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agaragar,

20

solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

25 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

30 Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agaragar,

25

solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

35 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metabydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or propellants as may be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

Actual dosage levels of active ingredients in the compositions of the present invention may be varied so

as to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors.

The total daily dose of the compounds of this invention administered to a host in single or divided dose may be in amounts, for example, of from about 1 nanomol to about 5 micromols per kilogram of body weight. Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight, general health, sex, diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

In another embodiment, the present invention is directed to a method of diagnosis comprising the administration of a diagnostic imaging effective amount of the compositions of the present invention to a mammal or to a tissue from said mammal in need of such diagnosis. A method for diagnostic imaging for use in medical procedures in accordance with this invention comprises administering to the body of a test subject in need of a diagnostic image an effective diagnostic image producing amount of the above-described compositions.

In this method, an effective diagnostic image producing amount of a non-radioactive targeting immunoreagent (NRIR) as described above in a pharmaceutically acceptable medium is administered to a patient and said non-radioactive targeting immunoreagent is allowed to accumulate at the target site such as at a

59

tumor site in said patient. Subsequently, a diagnostic imaging effective dose of a radioactive delivery reagent (RDA) as described above in a pharmaceutically acceptable medium is administered to said patient, and said radioactive targeting reagent is allowed to accumulate at the target site, said target site being the said non-radioactive targeting immunoreagent accumulated at said tumor site in said patient. The image pattern can then be visualized.

10 Alternatively, the NRTR may be reacted with a diagnostic imaging effective amount of a reagent comprised of a radionuclide prior to administration to the environs of a tissue of interest of a patient undergoing such diagnostic imaging, waiting for an effective period of time during which time said NRTR will bind to sites on cells of said tissue of interest and during which time unbound NRTR will be removed from the environs of said tissue and then obtaining an image as a function of time of all or part of said tissue of interest. When the image of all or part of said tissue of interest is optimal, a diagnostic imaging or a therapeutically effective amount of RDA containing the same or a different radionuclide as that employed on the NRTR is administered to said tissue of interest of said patient.

15 In addition to human patients, the test subjects can include mammalian species such as rabbits, dogs, cats, monkeys, sheep, pigs, horses, bovine animals and the like.

20 After administration of the compositions of the present invention, the subject mammal is maintained for a time period sufficient for the administered compositions to be distributed throughout the subject and enter the tissues of the mammal. A sufficient time period is generally from about 1 hour to about 2 weeks

25

30

35

or more and, preferably from about 2 hours to about 1 week.

5 The following examples further illustrate the invention and are not to be construed as limiting of the specification and claims in any way. Specific embodiments of the invention are illustrated in the following examples.

10 EXAMPLES
Example 1

5 $5\text{-(4'-Hydroxy-3',5'-dimethoxybenzyl)-2,4'-diaminopyrimidine}$

15

To a solution of 22 g (0.2 mol) of 2,4-diaminopyrimidine and 49.5 g (0.2 mol) of 2,6-dimethoxy-4'-(N,N-dimethylamino)methylphenol hydrochloride in 300 ml of ethylene glycol was added 11 g (0.203 mol) of sodium methoxide. The reaction mixture was heated under nitrogen with stirring to 150-160°C, at which point dimethylamine was evolved. After 3 hours, 80% of the theoretical amount of dimethylamine was collected. The solvent was removed in vacuo (at 85°C), the residual oil was washed with water, and then with acetone. The product was obtained as a tan precipitate (yield 25 g).

Example 2

30 $5\text{-(4'-Methoxycarbonylmethylbutoxy-3',5'-dimethoxybenzyl)-2,4'-diaminopyrimidine}$

35 $5\text{-(4'-Hydroxy-3',5'-dimethoxybenzyl)-2,4'-diaminopyrimidine}$ (5.52 g; 20 mmol) in 80 ml of DMSO was allowed to react with t-BuOH (2.469 g; 22 mmol) and methyl bromoacetate (3.366 g; 22 mM) for 14 hours. The

63

(4'-carboxymethoxy-3',5'-dimethoxybenzyl)-2,4-diaminopyrimidine (i.e., trimethoprim-4'-O-acetic acid) (5; 30mM) in 100 ml of methylene chloride. The resulting reaction mixture is stirred 2 days, and the solvent and the urea are removed to afford the blocked trimethoprim-4'-O-acetic acid heptapeptide (6), which upon mild hydrolysis with trifluoroacetic acid, yields trimethoprim-4'-O-acetic acid heptapeptide (7).

A solution of trimethoprim-4'-O-acetic acid heptapeptide (7) (20 mM) in 50 ml of a saturated aqueous sodium bicarbonate at about pH 9 is allowed to react with TMT-isothiocyanate (8; 20mM) at room temperature for 12 hours to afford trimethoprim-4'-O-acetic acid-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] (9).

A solution of the above trimethoprim-4'-O-acetic acid-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] (9) in deionized water buffered with 0.5 M sodium acetate at pH 6.0 at room temperature is treated with a solution of 90%⁹⁰YCl₃ in aqueous hydrochloric acid. Uptake of the radiolabel into the chelator is demonstrated by thin layer chromatography. In excess of 97% of the added ⁹⁰Y is associated with trimethoprim-4'-O-acetic acid-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] to form the desired ⁹⁰Y-labelled product.

25

Example 5

Preparation of radionuclide labeled ⁹⁰Y-methotrexate-D-Glu-(Ala)₄-Lys-(TMT)-Lys-(TMT) (Scheme 3)

30

To a mixture of resin containing D-Glu-(COOtBu)-(Ala)₄-[Lys-tBoc]-[Lys-(TMT)-Lys-(TMT)] (Scheme 3) of methylene chloride is added in portions a solution of 4'-carboxymethotrexate (11a; 30mM) in 100 ml of methylene chloride. The resulting reaction mixture is stirred 2 days, and the solvent and the urea are removed

64

to afford the blocked methotrexate-heptapeptide (10), which upon mild hydrolysis with 4 N HCl, yields 4'-carboxymethotrexate-heptapeptide (11).

To a solution of 4'-carboxymethotrexate-heptapeptide (11; 20 mM) in 50 ml of methylene chloride is allowed to react with TMT-isothiocyanate (8; 20mM) at room temperature for 12 hours to afford 4'-carboxymethotrexate-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] (12).

10 A volume of radioactive Yttrium chloride (⁹⁰Y in 0.04M hydrochloric acid at a specific activity of >500 Ci/mg; Amersham-Mediphysics) is neutralized using two volumes of 0.5 M sodium acetate pH 6.0 and added to a solution of the above 4'-carboxymethotrexate-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] (12) in deionized water buffered with 0.5 M sodium acetate at pH 6.0 at room temperature. The labeling is allowed to proceed for one hour and then the labeling efficiency is determined by thin layer chromatography on a Geiman ITAL-SG strip developed in 0.1 M sodium citrate, pH 6.0. In excess of 97% of the added ⁹⁰Y is taken up by the 4'-carboxymethotrexate-D-Glu-(Ala)₄-[Lys-(TMT)]-[Lys-(TMT)] to form the desired ⁹⁰Y-labeled product.

The following examples illustrate the construction of conjugates between an antibody and dihydrofolate reductase (DHFR). In these examples ING-1 (a chimeric IgG1 antibody) is chosen for the methodologies; other antibodies such as those described herein are useful. The DHFR referred to below is of bacterial origin, produced as a recombinant product from the cloned DHFR gene which is overexpressed in Escherichia coli (E. coli), or of human origin, available as a recombinant protein.

30

To a mixture of resin containing D-Glu-(COOtBu)-(Ala)₄-[Lys-tBoc]-[Lys-(TMT)-Lys-(TMT)] (Scheme 3) of methylene chloride is added in portions a solution of 4'-carboxymethotrexate (11a; 30mM) in 100 ml of methylene chloride. The resulting reaction mixture is stirred 2 days, and the solvent and the urea are removed

35

Examples of System A

65

SYSTEM A		
Non-Radioactive Targeting ImmunoReagent	Radioactive Delivery Agent	RDA
1 Immunoreactive group + (linking group + receptor) _n	Ligand + (chelating agent + radionuclide) _m	10
2 - (L ₁ -Rec) _n	D- (L ₂ -O-M) _m	
3 - (L ₁ -Rec) _n	Trimethoprim- (L ₂ -Q-M) _m	
4 - (L ₁ -Rec) _n	Methotrexate- (L ₂ -O-M) _m	15

Wherein:

2 is the residue of an immunoreactive group;

Rec is the residue of a receptor, preferably DHFR;

5 D is the residue of a ligand that has an affinity for non-covalent binding to the receptor, preferably a DHFR receptor;

DHFR ligand is the residue of a ligand that has an affinity for non-covalent binding to a DHFR active site;

TMP is the residue of a trimethoprim analog;

MTX is the residue of a methotrexate analog;

L₁ and L₂ are each independently the residue of a linking group that may independently contain spacing group;

Q is the residue of a chelating group;

M is a radionuclide; and

n and m are each independently an integer greater than zero.

20

Example 6

66

(6a) Preparation of Antibody-Maleimide with Sulfo-SMCC
[ING-1-Maleimide (2-1u)]

5 A sulfo-SMCC solution (36 nmoles) in PBS was added to a sample of a chimeric antibody (ING-1; 6 nmoles) solution in phosphate buffer (pH7). The resulting mixture was allowed to stand for 30 minutes with occasional mixing at room temperature. The reaction mixture was diluted with phosphate buffered saline, added to a prewashed PD-10 column (Pharmacia), and eluted with PBS to afford ING-1-maleimide. This material was stored on ice until use.

(6b) Preparation of mercaptoalkyl-antibody [2-L₁]

A sample of a chimeric antibody (ING-1; 6 nmoles) solution in 0.1 M carbonate buffer (pH 8.8) is mixed with 200 nmoles of an aqueous solution of 2-iminothiolane. The resulting mixture is allowed to stand for 30 minutes with occasional mixing at room temperature. The reaction mixture is diluted with phosphate buffered saline, added to a prewashed PD-10 column, and eluted with PBS to afford mercaptoalkyl-ING-1. This material is stored on ice until use.

(6c) Preparation of mercapto-antibody using SATA

30 A solution containing 6 nmoles of ING-1 in PBS is vortexed while 60 nmoles of SATA (in DMSO) are added. After mixing and standing at room temperature for 60 minutes, the reaction mixture is diluted with PBS, and eluted from a PD-10 column with PBS to afford ING-1-CO-CH₂-S-CO-CH₃. The acetylthioacetylated antibody is deprotected by the addition of 30 uL of a pH 7.5

35

67

solution containing 100 mM sodium phosphate, 25 mM EDTA, 50 mM NH₂OH. The reaction proceeds for two hours at room temperature after which the material is again passed down a PD-10 column by elution with PBS. The final product (ING-1-CO-CH₂-SH) is used immediately.

(6d) Radiolabeling of ING-1 with ¹²⁵I

An aliquot of ING-1 (500 ug) is labeled with ¹²⁵I monochloride (at about 5 mCi/mg) in the presence of iodogen (Sodium N-chloro-benzenesulfonamide) beads in a volume of 500 uL 100 mM phosphate buffer (pH 7.2) at room temperature. After 15 minutes the reaction is terminated by passage of the labeled antibody down a prewashed NAP-5 column (Pharmacia). The radioiodinated protein is eluted with PBS and stored at 4°C until use.

Example 7

(7a) Preparation of mercapto-DHFR using SATA

A solution containing 50 nmoles of DHFR in PBS is vortexed while 500 nmoles of SATA (in DMSO) are added. After mixing and standing at room temperature for 60 minutes, the reaction mixture is diluted with PBS, and eluted from a PD-10 column with PBS to afford DHFR-CO-CH₂-S-CO-CH₃. The acetylthioacetylated DHFR is deprotected by the addition of 25 uL of a pH 7.5 solution containing 100 mM sodium phosphate, 25 mM EDTA, 100 mM NH₂OH. The reaction proceeds for two hours at room temperature after which the material is again passed down a PD-10 column by elution with PBS. The final product, DHFR-CO-CH₂-SH is used immediately.

35

(7b) Preparation of mercaptoalkyl-DHFR

A sample of DHFR (150 nmoles) is dissolved in 0.1 M carbonate buffer (pH 9) and 2 nmoles of an aqueous solution of 2-iminothiolane are added. The reactants are vortex mixed and kept at room temperature for 120 minutes. The reaction mixture is quenched by the addition of 2 nmoles of ethanolaamine, diluted with phosphate buffered saline. The reaction mixture is added to a prewashed PD-10 column, and eluted with PBS to afford DHFR-RC(NH₂)⁺CH₂CH₂SH. For use in conjugation to maleimide-derivatized ING-1 (Example 6a), the product is eluted off the column directly into the antibody solution.

(7c) Preparation of reduced DHFR using dithiothreitol

A solution containing 40 nmoles of DHFR in PBS was vortexed and an equal volume of 500 mM dithiothreitol in PBS was added. After mixing and standing on ice for 60 minutes, the reaction mixture was eluted from a prewashed PD-10 column with PBS to afford DHFR-SH. For use in conjugation to maleimide-derivatized antibody (Example 6a), the product was eluted off the column directly into the antibody solution.

(7d) Preparation of DHFR-Maleimide using Sulfo-SMCC

A sulfo-SMCC solution (300 nmoles) in PBS is added to a sample of DHFR (50 nmoles) in phosphate buffer (pH 7). The resulting mixture is allowed to stand for 30 minutes with occasional mixing at room temperature. The reaction is stopped with 60 nmoles basic tris buffer. The reaction mixture is diluted with phosphate buffered saline, added to a prewashed PD-10 column, and eluted

68

(7e) Preparation of mercaptoalkyl-DHFR

A sample of DHFR (150 nmoles) is dissolved in 0.1 M carbonate buffer (pH 9) and 2 nmoles of an aqueous solution of 2-iminothiolane are added. The reactants are vortex mixed and kept at room temperature for 120 minutes. The reaction mixture is quenched by the addition of 2 nmoles of ethanolaamine, diluted with phosphate buffered saline. The reaction mixture is added to a prewashed PD-10 column, and eluted with PBS to afford DHFR-RC(NH₂)⁺CH₂CH₂SH. For use in conjugation to maleimide-derivatized ING-1 (Example 6a), the product is eluted off the column directly into the antibody solution.

(7f) Preparation of reduced DHFR using dithiothreitol

A solution containing 40 nmoles of DHFR in PBS was vortexed and an equal volume of 500 mM dithiothreitol in PBS was added. After mixing and standing on ice for 60 minutes, the reaction mixture was eluted from a prewashed PD-10 column with PBS to afford DHFR-SH. For use in conjugation to maleimide-derivatized antibody (Example 6a), the product was eluted off the column directly into the antibody solution.

(7g) Preparation of DHFR-Maleimide using Sulfo-SMCC

A sulfo-SMCC solution (300 nmoles) in PBS is added to a sample of DHFR (50 nmoles) in phosphate buffer (pH 7). The resulting mixture is allowed to stand for 30 minutes with occasional mixing at room temperature. The reaction is stopped with 60 nmoles basic tris buffer. The reaction mixture is diluted with phosphate buffered saline, added to a prewashed PD-10 column, and eluted

69

with PBS to afford DHFR-maleimide. This material is stored on ice until use.

(7e) Radiolabeling of DHFR with ^{125}I

An aliquot of DHFR (500 μg) is labeled with ^{125}I monochloride (at about 5 mCi/mg) in the presence of iodogen (Sodium N-chloro-benzenesulfonamide) beads in a volume of 500 μl 10mm phosphate buffer (pH 7.2) at room temperature. After 15 minutes the reaction is terminated by passage of the labeled protein down a prewashed NAP-5 column. The iodinated DHFR is eluted with PBS and stored at 4°C until use.

(7f) Alternative conjugation method that protects DHFR active site

In order to prevent the interaction of reagents with the active site of the DHFR enzyme during the derivatization process, the active site of the enzyme is blocked to prevent the entry of the reagents.

A methotrexate/agarose (Sigma) column resin slurry (1 ml; protected from light) is washed twice with a large volume of high salt buffer (100 mM KPO₄, 1.0 M KCl, 1.0 mM K₂EDTA and 0.5 mM dithioerythritol at pH 6.0) to remove any free methotrexate. The final centrifuged pellet is mixed with DHFR (1 nmole/5 mL) in 5.0 mL of buffer containing (50 mM KPO₄, 1.0 mM K₂EDTA and 0.5 mM dithioerythritol at pH 6.0) and left for one hour. The resin with the now attached DHFR is

centrifuged to a pellet and washed x3 with washing buffer (50 mM KPO₄, 1.0 mM K₂EDTA at pH 6.0). The resin pellet is suspended in a sulfo-SMCC solution (6 nmoles) in PBS (pH 7). The resulting mixture is stirred very slowly for 60 minutes at room temperature. The reaction is stopped by dilution with 10 mL of washing buffer and

70

the resin is again centrifuged to a pellet and washed 2x with the washing buffer. The resin is poured into a narrow glass Pasteur pipette whose exit is obstructed with a plug of glass wool. Maleimide derivatized DHFR is removed from the resin by elution with 30 mL of eluting buffer (100 mM folic acid, 200 mM KBO₃, 1.0 M KCl, 1.0 mM K₂EDTA at pH 9.0) to afford DHFR-maleimide. This material is pooled, dialysed against dialysis buffer (20 mM Tris, 1.0 mM K₂EDTA; pH 7.2) at 4°C overnight and then concentrated in a Centricon-10[®] (Amicon) device to a concentration of approximately 1.0 mg/mL protein. This material is then reacted with antibody containing a free sulfhydryl group.

The folate is removed from the active site of the enzyme by passage of the maleimide DHFR (Example 7a) or antibody-DHFR conjugate (see Example 8 below) through a DEAE-SEPHADYL column (Pharmacia). The column (~50 mL resin) is prewashed with DEAE-washing buffer (10 mM Tris, 1.0 mM K₂EDTA, 0.2 mM dithioerythritol; pH 7.2) and the protein loaded on in the same buffer. After washing, the protein is removed from the column with a non-linear gradient of 1000mL of DEAE-washing buffer (10 mM Tris, 1.0 mM K₂EDTA, 0.2 mM dithioerythritol; pH 7.2) to 1000 mL of 10 mM Tris, 0.5 M KCl, 1.0 mM K₂EDTA, 0.2 mM dithioerythritol; pH 7.2. Fractions eluting from the column are collected and monitored at 280 nm for protein content. Fractions containing protein are pooled, concentrated as before and dialysed overnight against PBS to produce folate-free material.

30

35

Example 8

(8a) Conjugation of DHER to antibody (formation of Z-Lys-RecI)

5 The methodologies for conjugation are essentially the same, irrespective of whether the maleimide group is on the antibody or on the DHER, and irrespective of the method chosen to introduce the sulphydryl group into the protein. The final molar ratio during the conjugation is maintained at close to equimolar antibody:DHER in order to control over-conjugation of the proteins which could result in inactivation of one or other or both. The following procedure is applicable to the conjugation of materials in Example 6 to the materials in Example 7.

10 Following reduction (see Example 7a), a sample (50 nmoles) of DHER (N)-CO-CH₂-SH is eluted off a PD-10 column directly into a solution of maleimide-derivatitized ING-1 (5 nmoles) prepared according to Example 6a. After a brief mixing, the reaction is allowed to proceed for 4 hours at room temperature. The antibody-DHER conjugate is transferred to a Centricon-30[®] concentrator, diluted with PBS, and concentrated down to a volume of approximately 500 μ L by centrifugation. The concentrated protein is then diluted with PBS to a volume of 3.0 mL and re-centrifuged to a volume of 500 μ L. This procedure, which separates unconjugated DHER and other low molecular weight products from the retained antibody-DHER and unconjugated antibody products, is repeated 4 times or until spectrophotometric monitoring of the filtrate at 280 nm shows that no further protein is being filtered.

15 Finally, the material in the Centricon-30[®] is concentrated to approximately 1.0 mg ING-1-DHER per

milliliter solution and applied to a 2.6 x 60 cm Sephadryl S-200 size-exclusion column equilibrated and eluted with 50 mM sodium phosphate buffer at pH 7.2 supplemented with 150 mM sodium chloride. This column separates unconjugated antibody from antibody-DHER conjugate. Fractions of the eluate containing the conjugate are pooled and then centrifuged in a Centricon-30 device to a concentration of approximately 1.0 mg, ING-1/DHER, per milliliter solution. The conjugate is sterile filtered through a 0.22 μ filter and stored at 4°C until use.

10 Addition of trace amounts of either 125I-labeled DHER or 125I-labeled ING-1 to the reaction mixtures, allows the ratio of one protein to the other after conjugation to be calculated.

(8b) Conjugation of reduced DHER to Antibody-maleimide (Scheme 1)

20 Following reduction, a sample (50 nmoles) of DHER-SH (Example 7c) was eluted off a PD-10 column directly into a solution of maleimide-derivatitized ING-1 (5 nmoles) prepared according to Example 6a. After a brief mixing, the reaction was allowed to proceed for 4 hours at room temperature. The antibody-DHER conjugate was transferred to a Centricon-30[®] concentrator, diluted with PBS, and concentrated down to a volume of approximately 500 μ L by centrifugation. The concentrated protein was then diluted with PBS to a volume of 3.0 mL and re-centrifuged to a volume of 500 μ L. This procedure, which separates unconjugated DHER and other low molecular weight products from the retained antibody-DHER and unconjugated antibody products, was repeated three times. Finally, the material in the Centricon-30[®] was concentrated to approximately 1.0 mg ING-1-DHER per milliliter solution and applied to a 10 x 300 mm

25 30 35

5 Superose 12 FPLC size-exclusion column equilibrated and eluted at 1 mL/min with 50 mM sodium phosphate buffer (pH 7.2) supplemented with 150 mM sodium chloride. The optical density of the eluate was continuously monitored at 280 nm and fractions (1.0 mL) containing the antibody-DHFR conjugate were pooled. The protein concentration of the pooled material was assayed and the conjugate was stored at 4°C until use.

Examples of System B

SYSTEM B

	Non-Radioactive Targeting ImmunoReagent	Radioactive Delivery Agent	RDA
1	Immunoreactive group + (linking group + ligand) _n	Receptor + (linking group + chelating agent + radionuclide) _m	
2	Z-(L ₁ -DHFR ligand) _n	Rec-(L ₂ -Q-M) _m	
3	Z-(L ₁ -TRP) _n	Rec-(L ₂ -Q-M) _m	
4	Z-(L ₁ -MTX) _n	Rec-(L ₂ -Q-M) _m	

wherein:

Z is the residue of an immunoreactive group;

5 Rec is the residue of a receptor, preferably a DHFR receptor;

D is the residue of a ligand that has an affinity for non-covalent binding to the receptor, preferably to a DHFR receptor;

6 DHFR ligand is the residue of a ligand that has an affinity for non-covalent binding to a DHFR active site; TRP is the residue of a trimethoprim analog;

MTX is the residue of a methotrexate analog;

L₁ and L₂ are each independently the residue of a linking group that may independently contain spacing group;

Q is the residue of a chelating group;

M is a radionuclide; and

n and m are each independently an integer greater than zero.

20

Example 9

(9a) Preparation of Antibody-Maleimide with Sulfo-SMCC (ING-1-Maleimide)

5

This product is prepared according to the procedure of Example 6a.

(9b) Preparation of trimethoprim-4'-O-acetic acid cysteine

10

To a mixture of resin containing L-Cys (COO-trityl) (30 mM; Advanced Chem Tech) and DCC in 150 ml of methylene chloride is added in portions a solution of 5-(4'-O-acetic acid) (30 mM) in 100 ml of methylene chloride. The resulting reaction mixture is stirred 2 days, and the solvent and the urea are removed to afford the blocked trimethoprim-4'-O-acetic acid cysteine, which upon mild hydrolysis with trifluoroacetic acid, yields trimethoprim-4'-O-acetic acid cysteine.

20

(9c) Conjugation of trimethoprim-4'-O-acetic acid cysteine to Antibody (formation of 7-Ig-REC)

25

Trimethoprim-4'-O-acetic acid cysteine (50 nmoles) prepared according to Example 9b is added directly into a solution of maleimide-derivatized ING-1 (5 nmoles) prepared according to Example 9a. After a brief mixing the solution is then allowed to proceed for 4 hours at room temperature with intermittent stirring. The antibody-trimethoprim conjugate is transferred to a Centriflon-30® concentrator and diluted with PBS. After concentrating the protein down to a volume of approximately 500 µl by centrifugation, the material is again diluted with PBS to 3.0 ml and recentrifuged. This procedure, which separates unconjugated

trimethoprim and other lower molecular weight products from the retained antibody-trimethoprim and unconjugated antibody products, is repeated 4 times. Finally, the material in the Centriflon-30® is concentrated to approximately 10 mg ING-1-trimethoprim per milliliter solution and applied to a 2.6 x 60 cm Sepharose 5-200 size-exclusion column equilibrated and eluted with 50 mM sodium phosphate buffer at pH 7.2 supplemented with 150 mM sodium chloride. This column separates unconjugated antibody from antibody-trimethoprim conjugate.

Fractions of the eluate containing the conjugate are pooled and then centrifuged in a Centriflon-30® device to a concentration of approximately 1.0 mg ING-1-trimethoprim per milliliter solution. The conjugate is sterile filtered through a 0.22 filter and stored at 4°C until use.

Example 10

(10a) Conjugation of DFR to TMT (formation of REC-12-O)

20

Tetrapyridine methylenetetraacetic acid (TMT) or a suitable derivative thereof can be conjugated to a protein molecule (DFR) to yield a protein-TMT conjugate. The DFR referred to below is of either bacterial origin, produced as a recombinant product from the cloned DFR gene which is overexpressed in E. coli, or of human origin available as a recombinant protein. DFR (50 nmoles) is allowed to react with TMT-isothiocyanate (250 nmoles in 1.0 M carbonate, 150 mM sodium chloride buffer, pH 9.3 in an acid washed, conical, glass reaction vial. The solution is stirred briefly to mix the reactants and then left in the dark at room temperature. After 16 hours, the DFR/TMT conjugate is separated from unconjugated TMT, by applying the reaction mixture to a PD-10 chromatography column, which has been pre-washed and equilibrated with

5

10

15

20

25

30

35

50 mM sodium acetate buffer containing 150 mM sodium chloride at pH 5.6. The pure conjugate is eluted off the column with 2.5 mL of that same buffer, and concentrated on a Centrificon-10[®] concentration device.

5 (10b) Radiolabeling of DHFR/TMT with 90Y: (formation of Rec-1/2-0-M1m).

A volume of radioactive Yttrium chloride (90Y in 0.04 M hydrochloric acid at a specific activity of >500 Ci/g; Amersham-Mediphysics) is neutralized using two volumes of 0.5 M sodium acetate pH 6.0. The neutralized 90Y (1.0 μCi) is added to 1.0 mL of DHFR/TMT (1 mg/mL) in 50 mM sodium acetate buffer containing 150 mM sodium chloride at pH 5.6. The labeling is allowed to proceed for one hour and then the reaction mixture is loaded onto a PD-10 chromatography column which has been pre-washed and equilibrated in a buffer containing 50 mM sodium phosphate with 150 mM sodiumchloride pH 7.4 (PBS). The sample is eluted from the column with 1.5 mL of PBS. Fractions of radiolabeled DHFR/TMT (0.5 mL) are collected, assayed for radioactivity, and pooled. The labeling efficiency is determined by removing 1.0 μL of the sample and spotting it on to a Gelman ITC-SG strip.

10 The strip is developed in a glass beaker containing 0.1 M sodium citrate, pH 6.0 for a few minutes until the solvent front has reached three-quarters of the way to the top of the paper. The strip is inserted into a System 200 Imaging Scanner (Bioscan) which has been optimized for 90Y and is controlled by a Compaq 386/20 computer. In this system free 90Y migrates at the solvent front while the DHFR/TMT (90Y) remains at the origin. Using this system more than 98% of the total 90Y radioactivity is found associated with DHFR/TMT at the origin.

15 Example 11
Assays on the DHFR conjugates prepared from System A or System B

20 (11a) Protein Concentration

The concentrations of ING-1 and DHFR for use in the conjugate reactions are determined by the BioRad protein assay (BioRad Catalog # 500-0001) using bovine immunoglobulin as the protein standard. By inclusion of trace amounts of 125I-labeled DHFR or ING-1 in the reaction mixtures, and by knowing the specific activity of the preparations, the ratio of one protein to the other after conjugation is calculated.

25 As an alternative to radiolabelling, the DHFR can be tagged with other materials (e.g., TMT (for use with 90Y or Europium fluorescence), biotin, fluorescein isothiocyanate (FITC) etc. to detect and quantify the amount of DHFR present in a solution or conjugated to another protein.

30 (11b) Immunoactivity assay by Flow Cytometry

Conjugates of antibody-DHFR (e.g., Example 8) or antibody-trimethoprim (e.g., Example 10) are examined for their ability to bind to antigens on the surface of a human tumor cell line to which the antibody had been raised. The immunoreactivity of the conjugates is compared by flow cytometry with a standard preparation obtained from the American Type Tissue Collection: ATCC

35 Target HT-29 cells (a human adenocarcinoma cell line are grown to confluence in tissue culture flasks using McCoy's media supplemented with 10% fetal calf serum. The cells are harvested by scraping the flask walls with a cell scraper. Cells from many separate flasks are pooled, centrifuged to a pellet, resuspended at 5x10⁵/mL

in a solution of ice-cold 50 mM sodium phosphate with 150 mM sodium chloride buffer pH 7.4 (PBS) supplemented with 0.1% bovine serum albumin (Sigma) and 0.02% sodium azide (Flow buffer). The cells are washed in this same buffer and then counted. An antibody standard curve is constructed by diluting a stock solution of ING-1 with an irrelevant (non-binding), isotype-matched control antibody (human IgG1), to give a number of samples ranging in ING-1 content from 10% to 100%. The standard curve is made in flow buffer so that each sample contains 1.0 mg protein per mL. Samples from the standard curve and ING-1-DHFR unknowns, or ING-1-trimethoprim unknowns are then incubated with 5x10⁵ HT29 cells at 4°C for 1 hour. After extensive washing 10 to remove unbound antibody, the cells are resuspended in 100 uL flow buffer and incubated at 4°C for 1 hour with goat-anti-human antibody labelled with fluorescein isothiocyanate. After further washing in flow buffer the samples are analyzed by flow cytometry on a Coulter EPICS 753 flow cytometer. Fluorescein isothiocyanate (FITC) and propidium iodide (PI) are excited using the 488 nm emission line of an argon laser. The output is set at 500 mw in light regulation mode. Single cells are identified by 90 degree and forward angle light scatter. Analysis windows are applied to these parameters to separate single cells from aggregates and cell debris. Fluorescence from FITC and propidium are separated with a 550 nm long pass dichroic filter and collected through a 530 nm band pass filter (for FITC), and a 635 nm band pass filter (for PI). Light scatter parameters are collected as integrated pulses and fluorescence is collected as log integrated pulses. Dead cells are excluded from the assay by placing an analysis window on cells negative for PI uptake. The mean fluorescence per sample (weighted average from 2500 cells) is calculated for each histogram. FITC calibration beads are analysed

80

in each experiment to establish a fluorescence standard curve. The average fluorescence intensity for each sample is then expressed as the average FITC equivalents per cell. Immunoreactivity is calculated by comparing the average fluorescence intensity of the ING1-DHFR or ING-1-trimethoprim sample with values from the standard curve.

(11c) Immunoreactivity assay by ELISA

10

The antigen to which the antibody, ING-1, binds is prepared from LS174T or HT-29 cells (available from ATCC) by scraping confluent monolayers of cells from the walls of culture flasks with a cell scraper. The cells from many flasks are combined and a sample is taken and counted to estimate the total number of cells harvested. At all times the cells are kept on ice. Following centrifugation of the cells at 1500 rpm for 10 minutes at 4°C, the cells are washed once in 25 mL ice-cold 50 mM sodium phosphate buffer, pH 7.4 supplemented with 150 mM sodium chloride (PBS), pelleted under the same conditions and transferred in 10 mL PBS to an ice-cold glass mortar. The cells are homogenized at 4°C using a motor-driven pestle and then centrifuged at 3000 x g for 5 minutes. The antigen-rich supernatant is removed from the other cell debris and subjected to further centrifugation at 100,000 x g for one hour at 4°C. The pellet (antigen fraction) from this final step is suspended in 100 uL of PBS for every million cells harvested. Following an estimate of the protein concentration (BioRad BCA protein assay using bovine immunoglobulin as the protein standard) the antigen is stored at -20°C until use.

Each well of a 96-well Costar microtiter plates is

coated with antigen by adding 100 uL/well of cell lysate (10 mg/ml) prepared as above. The microtitre plates are

5

15

20

25

30

35

81

allowed to dry overnight in a 37°C incubator. After washing the plate five times with 0.05% Tween-20 (Sigma), they were blotted dry. The wells of each plate were blocked by adding 125 μ L/well of a 1% BSA (bovine serum albumin, Sigma) solution in PBS and incubated for 1 hour at room temperature. The plates were washed five times with 0.05% Tween-20. Samples (50 μ L/well in duplicate) of ING-DHFR or ING-trimethoprim conjugates and standard ING-1 antibody solutions are prepared at a range of concentrations in 1% BSA in PBS. Biotinylated ING-1 (1.0 mg/mL in 0.1% BSA) is added to each well (50 μ L/well) and the plates are then incubated for 2 hours at room temperature. Following five washes with 0.05% Tween-20, the plates are blotted dry and incubated at room temperature for one hour with dilute (1:2000 in 0.1% BSA) streptavidin-alkaline phosphatase (Tago). After a further five washes, color is developed in each well upon the addition of 100 μ L per well of phosphate substrate reagent (Sigma). After one hour at room temperature, the color is read using a 405 nm filter in a Titertek Multiscan microplate reader.

(11d) SDS PAGE gel electrophoresis

25 Samples of ING-1-DHFR or ING-1-trimethoprim conjugates are subjected to electrophoresis on Novex 8-16% reduced and native polyacrylamide gels using SDS buffers to estimate their apparent molecular weight and the degree of heterogeneity of the preparation. Using standards of known molecular weight run on the same gel, a standard curve is constructed of the distance travelled versus the log of the molecular weight. From this standard curve the relative molecular weights of the bands associated with each conjugate preparation are determined.

82

(11e) Determination of aggregate formation by size-exclusion HPLC

5 A 30 cm x 7.5 mm TSK-G3000SW size-exclusion HPLC column (Supelco) fitted with a guard column of the same material is equilibrated with 12 column volumes of 10 mM sodium phosphate buffer pH 6.0 supplemented with 150 mM sodium chloride using a Waters 600E HPLC system with a flow rate of 1.0 mL per minute at 400-600 PSI. A sample (25 μ L) of BioRad gel filtration protein standards is injected on to the column. The retention time of each standard is monitored by a Waters 490 UV detector set at 280 nm. Following the recovery of the final standard, the column is washed with a further 10 volumes of 10 mM sodium phosphate buffer pH 6.0 supplemented with 150 mM sodium chloride. Samples (50 μ L) of either native ING-1 antibody or ING-1-DHFR at 200 μ g/mL are injected on to the column and their retention times recorded. From the areas of the retained peaks and the retention time, the amount of aggregated material in the ING-1-DHFR or ING-1-trimethoprim conjugates sampled are calculated.

(11f) Determination of DHFR activity

25 Among other things, the enzymatic activity of DHFR is used to monitor:

- 1) Preservation of enzyme activity in a manner analogous to measuring the binding of the antibody to it's antigen, the activity of the enzyme before and after conjugation is assayed to ensure that the act of conjugation does not inhibit the enzyme;
- ii) inhibitory effect of drugs (e.g., trimethoprim and the trimethoprim analogs described above in Examples 1-5) on both free and antibody-conjugated DHFR;
- iii) to assay the effect of the trimethoprim-based TMR [90%] delivery system; and

iv) measurement of the amount of DHEF in a

According to the 1992 Sigma Chemical Company catalog on Page 350, DHFR activity is defined in terms of units; one said unit of DHFR enzyme activity is defined as the amount of material needed to convert 1 micromole of 7,8-dihydrofolic acid and the reduced form of β -nicotinamide adenine dinucleotide phosphate (NADPH) to 5,6,7,8-tetrahydrofolate and the oxidized form nicotinamide adenine dinucleotide phosphate (NADP) minute at pH 6.5 and 25°C.

The activity of the enzyme was measured spectrophotometrically at 340 nm by following the rate of oxidation of NADPH to NADP during the reduction of dihydrofolate to tetrahydrofolate. An aliquot (5 μ l) of a freshly thawed solution of the enzyme subunit (7,8, dihydrofolic acid (5.44 mM) was treated with β -mercaptoethanol and 600 μ l of 100mM Imidazole buffer pH 7.0. To measure the enzyme activity of DHFR, the reaction mixture contained 20 μ l (3.2 mg/mL) of NADPH, 20 μ l of the above 7,8, dihydrofolic acid mixture, 955 μ l 100mM Imidazole buffer pH 7.0. A sample (5 μ l) of protein) of DHFR was added to the prewarmed (25°C) reaction mixture, mixed rapidly, and the change in optical density at 340 nm was monitored every 5 seconds for a total of 120 seconds in a Shimadzu 124 ultraviolet spectrophotometer. The activity (units/mg protein) was calculated from the slope of the optical density

Inhibition of DHEA activity 1119

Trimethoprim (TMP) or the trimethoprim-4'-acetic acid amide of $H_2N\text{-}[D\text{-Glu}]\text{-Ala-Ala-Lys-Lys-OH}$ (TMP-peptide: Example 3), in a range of concentrations, was preincubated with samples of DHEF or ING-1-DHEF.

conjugates (Example 8b) for 2 minutes. The activity of DHFR was then assayed as before (Example 11f) and the concentration of TMP or TMP-peptide required to produce 50% inhibition of enzyme activity (IC₅₀) was calculated.

Inhibitor	DIFPR alone	ING-1/DIFPR Conjugate IC ₅₀	Concentration	Concentration
TMP	< 1.0 nMolar	1.0 nMolar		
TIP-Peptide	4.2 nMolar	1.0 nMolar		

(11) Quantitation of DEFR in TNG-1-DEER conjugates.

A sample (1.2 µg of protein) of ING-1/DHFR conjugate (from Example 8b) was used in place of DHFR in assay for enzyme activity (Example 11f). The activity of the conjugate (units/ml) was calculated from the slope of the optical density vs time plot as before. The activity of the conjugate prepared in Example 11e and the activity of a known standard amount of unconjugated DHFR, the average number of molecules of conjugated to each antibody molecule was calculated found to be 0.34 moles of DHFR per mole of antibody.

(318)

conjugal
the active
the static
From 8a
8b and
uncon-
DHEFR
and fo-

The present invention has been described in detail with particular reference to certain preferred embodiments thereof, but it will be understood that variations and modifications can be effected within the spirit and scope of the invention.

8

35

We claim:

1. A non-radioactive targeting immunoagent that comprises an immunoactive material, the residue of one or more receptor moieties or ligands which have an affinity for non-covalent binding to a receptor moiety, and one or more linking groups.

10 2. A radioactive targeting immunoagent that comprises the residue of a receptor moiety or a ligand which has an affinity for non-covalent binding to a receptor moiety, one or more chelating agents, one or more linking groups and one or more radionuclides.

15 3. A targeting immune reagent that comprises moieties represented by the structure
 $Z-(L1-X)_n$
 wherein:
 20 Z comprises the residue of an immunoreactive protein;

$L1$ is a chemical bond or a linking group that may contain a spacing group;
 X is the residue of a receptor moiety or a ligand which has an affinity for non-covalent binding to a receptor moiety; and
 n is an integer greater than zero.

25 4. A radioactive targeting reagent comprised of moieties represented in the structure
 $D-(L2-Q-M)_m$
 wherein:
 D is the residue of a receptor moiety or a ligand which has an affinity for non-covalent binding to a receptor moiety;

30 Q is the residue of a chelating group;
 M is a radionuclide; and
 m is an integer greater than zero.

5 5. The reagent of claim 3 wherein Z is the residue of an antibody or antibody fragment.

10 6. The reagent of claim 5 wherein the antibody is selected from ING-1; B72.3; 9.2.27; D612; U113A; NRNU-10; 7E11C5; CC49; TNT; PR1A3; B174; B43; and anti-HLB antibodies.

15 7. The reagent of claim 3 wherein X is the residue of dihydrofolate reductase.

20 8. The reagent of claim 7 wherein the residue of dihydrofolate reductase is derived from *Escherichia coli* strain CV634 transformed with the Plasmid pCV79.

25 9. The reagent of claim 3 wherein X is selected from the group consisting of residues of trimethoprim analogues and residues of methotrexate analogs.

30 10. The reagent of claim 3 wherein $L1$ is comprised of the residue of a heterobifunctional cross-linking reagent.

35 11. The reagent of claim 10 wherein the heterobifunctional cross-linking reagent is selected from the group consisting of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl (4-iodoacetyl)aminobenzoate, sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate, 2-iminothiolane, and N-succinimidyl S-acetylthioacetate.

87

12. The reagent of claim 3 wherein L_1 is comprised of the residue of a modified receptor moiety containing a reactive functional group.

13. The reagent of claim 12 wherein the reactive functional group is selected from the group consisting of amino groups and sulfhydryl groups.

14. The reagent of claim 4 wherein D is selected from the group consisting of residues of trimethoprim analogues and residues of methotrexate analogs.

15. The reagent of claim 4 wherein D is the residue of dihydrofolate reductase.

16. The reagent of claim 15 wherein the residue of dihydrofolate reductase is derived from *Escherichia coli* strain CV634 transformed with the plasmid pCV29.

17. The reagent of claim 4 wherein L_2 is the residue of a heterobifunctional cross-linking reagent.

18. The reagent of claim 17 wherein the heterobifunctional cross-linking reagent is selected from the group consisting of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl (4-iodoacetyl)aminobenzoate, sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate, 2-iminothiolane, and N-succinimidyl S-acetylthioacetate.

19. The reagent of claim 4 wherein L_2 is the residue of a modified ligand moiety containing a reactive functional group.

35

88

20. The reagent of claim 19 wherein the reactive functional group is selected from the group consisting of amino groups and sulfhydryl groups.

21. The reagent of claim 4 wherein Q contains a polycarboxylic acid group.

22. The reagent of claim 4 wherein Q is selected from the group consisting of B4A, P4A, TMT, DCDTPA, PhabM, macroPhenM, and macroTMT.

23. The reagent of claim 4 wherein M is a radioactive isotope of a metal.

24. The reagent of claim 23 wherein the radioactive isotope is selected from 212Pb, 212Bi, 90Y, 177Lu, 186Re, 188Re, 64Cu, 67Cu, 99mTc, 111In, and 87Y.

25. A method of making a compound of the structure:
$$Z-(L_1-X)_n$$
 wherein:
 Z comprises the residue of an immunoreactive protein;

L_1 is a chemical bond or a linking group that may contain a spacing group;
 X is the residue of a receptor moiety or the residue of a ligand which has an affinity for non-covalent binding to a receptor moiety; and
 n is an integer greater than zero;

comprising:
(1) reacting X with a precursor to a residue of L_1 under conditions and for a time period sufficient to form a covalent complex which is a precursor to a residue of L_1-X ; and

35

(ii) reacting Z with the precursor to the residue of L₁-X produced in step (i) under conditions and for a time period sufficient to form a covalent complex Z-(L₁-X)_n.

5 26. The method of claim 25, wherein step (ii) comprises:

(iia) reacting Z with a precursor to the residue of L₁ under conditions and for a time period sufficient to form a covalent complex which is a precursor to a residue of Z-(L₁)_n; and
10 (iib) reacting the precursor to a residue of Z-(L₁)_n produced in step (iia) with a precursor to a residue of L₁-X under conditions and for a time period sufficient to form a covalent complex Z-(L₁-X)_n.

15

27. A method of making a compound of the structure:

D-(L₂-Q-X)_m

wherein:

20 D is the residue of a receptor moiety or the residue of a ligand which has an affinity for non-covalent binding to a receptor moiety;

L₂ is a chemical bond or a linking group that may contain a spacing group;

Q is the residue of a chelating group;

M is a radionuclide; and

m is an integer greater than zero;

comprising:

(i) reacting Q with a precursor to a residue of L₂ under conditions and for a time period sufficient to form a covalent complex which is a precursor to a residue of L₂-Q

30 comprising:
(ii) reacting D with the precursor to the residue of L₂-Q produced in step (i) under conditions and for a time period sufficient to form a covalent complex D-(L₂-Q)_m; and

35

5 28. The method of claim 27, wherein step (ii) comprises:
10 (iia) reacting D with a precursor to a residue of L₂ under conditions and for a time period sufficient to form a covalent complex which is a precursor to a residue of D-(L₂)_m; and
15 (iib) reacting the precursor to the residue of D-(L₂)_m produced in step (iia) with a precursor to a residue of L₂-Q under conditions and for a time period sufficient to form a covalent complex D-(L₂-Q)_m.

20 29. The method of claim 25 wherein Z is an antibody or antibody fragment.

25 30. The antibody of claim 29 wherein the antibody is selected from ING-1; B72.3; 9.2.27; D612; U13A; NRU-10; 7E11C5; CC49; TNT; PR1A3; B174; B43; and anti-HLB antibodies.

30 31. The method of claim 25 wherein X is selected from the group consisting of residues of trimethoprim analogs and residues of methotrexate analogs.

35 32. The method of claim 25 wherein L₁ is comprised of the residue of a heterobifunctional cross-linking reagent.

33. The method of claim 32 wherein the heterobifunctional cross-linking reagent is selected from the group consisting of sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate, sulfosuccinimidyl (4-iodoacetyl)aminobenzoate,

91

sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate, 2-iminothiolane, and N-succinimidyl S-acetylthioacetate.

34. The method of claim 25 wherein L₁ is comprised of the residue of a modified nucleotide moiety containing a reactive functional group.

35. The method of claim 34 wherein the reactive functional group is selected from the group consisting of amine groups and sulfhydryl groups.

36. The method of claim 25 wherein X is the residue of dihydrofolate reductase.

37. The method of claim 36 wherein the residue of dihydrofolate reductase is derived from *Escherichia coli* strain CV634 transformed with the plasmid pCV29.

38. The method of claim 28 wherein D is selected from the group consisting of residues of trimethoprim analogs and residues of methotrexate analogs.

39. The method of claim 28 wherein D is the residue of dihydrofolate reductase.

40. The method of claim 39 wherein the residue of dihydrofolate reductase is derived from *Escherichia coli* strain CV634 transformed with the plasmid pCV29.

41. The method of claim 28 wherein L₂ is comprised of the residue of a heterobifunctional cross-linking reagent.

42. The method of claim 41 wherein the heterobifunctional cross-linking reagent is selected from the group consisting of sulfosuccinimidyl 4-(N-

92

maleimidomethyl) cyclohexane-1-carboxylate, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate, 2-iminothiolane, and N-succinimidyl S-acetylthioacetate.

43. The method of claim 41 wherein L₂ is a residue of a ligand moiety containing a reactive functional group.

44. The method of claim 43 wherein the reactive functional group is selected from the group consisting of amine groups, carboxylate groups, hydroxyl groups, and sulfhydryl groups.

45. The method of claim 28 wherein Q contains a polycarboxylic acid group.

46. The method of claim 28 wherein Q is selected from the group consisting of B4A, P4A, TMT, DCDTPA, PhenT, macroPhenT, and macroTMT.

47. The method of claim 28 wherein M is a radioactive isotope of a metal.

48. The method of claim 47 wherein the radioactive isotope is selected from 212Pb, 212Bi, 90Y, 177Lu, 186Re, 188Re, 64Cu, 67Cu, 99mTc, 111In, and 87Y.

49. A pharmaceutical composition comprising a compound of claim 3 dissolved or dispersed in a pharmaceutically acceptable carrier.

50. A pharmaceutical composition comprising a compound of claim 4 dissolved or dispersed in a pharmaceutically acceptable medium.

35

93

51. A method of treating a tumor in a mammal comprising administering to said mammal an effective dose of a non-radioactive targeting immunoreagent of claim 3 in a pharmaceutically acceptable medium, waiting for a time period sufficient for said non-radioactive targeting immunoreagent to accumulate at the tumor site in said mammal, and subsequently, administering an effective dose of a radioactive targeting reagent of claim 4 in a pharmaceutically acceptable medium to said mammal, and waiting for a time period sufficient for said radioactive targeting reagent to accumulate at the target site, said target site being the said non-radioactive targeting immunoreagent accumulated at said tumor site in said mammal.

15

52. A method of diagnostic imaging in a mammal comprising administering to said mammal an imaging effective dose of a non-radioactive targeting immunoreagent of claim 3 in a pharmaceutically acceptable medium, waiting for a time period sufficient for said non-radioactive targeting immunoreagent to accumulate at the imaging site in said mammal, and subsequently, administering an effective dose of a radioactive targeting reagent of claim 4 in a pharmaceutically acceptable medium to said mammal, and waiting for a time period sufficient for said radioactive targeting reagent to accumulate at the target site, said target site being the said non-radioactive targeting immunoreagent accumulated at said imaging site in said mammal, and generating an image of said mammal.

53. The reagent of claim 3 wherein X is a residue of a receptor moiety and z and X comprise a fusion protein.

94

54. The reagent of claim 53 wherein the receptor moiety is dihydrofolate reductase.

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/11842

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/11842

A. CLASSIFICATION OF SUBJECT MATTER

IPC10 : A61K 49/02, 43/00; G01N 33/53
US CL : 435/6, 7.1, 7.2, 7.23, 7.9, 26; 42/41.1, 9, 85.8

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.2, 7.23, 7.5, 7.9, 26; 42/41.1, 9, 85.8

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Character of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Controlled Release, Volume 11, No. 1-3, issued 1989, V.P. Torchilin et al, "Antibody-Linked Cheating Polymers for Immunoinaging <i>In Vivo</i> ", pages 297-303, especially the Abstract.	1-5, 12, 13, 19, 20, 23, 24, 52
Y	Cancer Research, Volume 51, issued 01 November 1991, G. Papandili et al, "Three-Step Monoclonal Antibody Tumor Targeting in Carcinoembryonic Antigen-positive Patients", pages 5960-5966, especially the Abstract.	6, 10, 11, 17, 18, 21, 22, 25-30, 32-35, 41-51, 53
X	Journal of Nuclear Medicine, Volume 28, No. 8, issued 1-5, 12, 13, 19, August 1987, D.J. Hnatowich et al, "Investigations of Avidin 20, 23, 24, 52 and Biotin for Imaging Applications", pages 1294-1302, especially the Abstract, the lower right-hand column of page 1295, and the upper left-hand column of page 1296.	6, 10, 11, 17, 18, 21, 22, 25-30, 32-35, 41-51, 53
Y	Journal of Nuclear Medicine, Volume 28, No. 8, issued 1-5, 12, 13, 19, August 1987, D.J. Hnatowich et al, "Investigations of Avidin 20, 23, 24, 52 and Biotin for Imaging Applications", pages 1294-1302, especially the Abstract, the lower right-hand column of page 1295, and the upper left-hand column of page 1296.	6, 10, 11, 17, 18, 21, 22, 25-30, 32-35, 41-51, 53

 Further documents are listed in the continuation of Box C. See parent family entries.

Special categories of cited documents:

"A" documents defining the general area of the art which is not considered to be part of particular relevance

"C" earlier documents published on or after the international filing date, documents which, may throw doubt on priority claim(s) or which is cited to establish the publication date of another claim or other special reasons (see specification)

"D" documents published prior to the international filing date but later than the priority date claimed

"E" documents published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"F" documents of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"G" documents of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"I" documents which are members of the same patent family

Date of mailing of the international search report
APR 06 1994

30 MARCH 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Faximile No. (703) 305-3230Authorized officer
Toni R. Schaefer
Telephone No. (703) 305-0196

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/11842

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG: Medline, CAB Abstracts, Biois, Embase, Cancerlit, Derwent, Automated Patent System
SEARCH TERMS: imaging, target?, sequential, pretarget?, post label?, dihydrofolate reductase, antibody?, radiolabel?,
radioisotope, isotope, vivo, two step, three step, trimethoprim, methotrexate, Snow R A, Krue L I, Black C D V,
Sherman C W

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.